

# CITATION REPORT

List of articles citing

*ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer*

DOI: 10.1200/jco.2006.08.2644

Journal of Clinical Oncology, 2006, 24, 5313-27.

**Source:** <https://exaly.com/paper-pdf/41304609/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1260	Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients. <b>1992</b> , 34, 219		1
1259	Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9. <b>1994</b> , 20, 737		1
1258	Newer pathologic assessment techniques for colorectal carcinoma. <b>2007</b> , 13, 6871s-6s		33
1257	A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer. <b>2007</b> , 73, 9-20		17
1256	Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. <b>2007</b> , 4, 316-21		47
1255	Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. <b>2007</b> , 132, 1239-46		71
1254	CA 19-9 and pancreatic carcinoma, a revival?. <b>2007</b> , 30, 12-3		2
1253	Realizing the Promise of Pharmacogenomics: Opportunities and Challenges. <b>2007</b> , 26, 261-291		4
1252	Carcinoembryonic antigen monitoring for early detection of asymptomatic incurable metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1293-4; author reply 1294	2.2	3
1251	p66 Shc tumor levels show a strong prognostic correlation with disease outcome in stage IIA colon cancer. <b>2007</b> , 13, 5798-804		34
1250	In Reply. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1293-1293	2.2	3
1249	The features of host immune response with respect to microsatellite status of colorectal cancer. <b>2007</b> , 15, 5-9		
1248	Potential chemotherapy options in the triple negative subtype of breast cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1294-5; author reply 1295-6	2.2	11
1247	In Reply. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1294-1294	2.2	6
1246	Comparative outcome between chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision in rectal cancer. <b>2007</b> , 246, 754-62		61
1245	Progress on molecular markers of pancreatic cancer. <b>2007</b> , 23, 508-14		42
1244	Antigène carcinoembryonnaire. <b>2007</b> , 2, 1-5		

1243	Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. <b>2007</b> , 43, 1348-60		363
1242	Current immunotherapeutic strategies in pancreatic cancer. <b>2007</b> , 16, 919-43, xi		7
1241	The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. <b>2007</b> , 67, 1883-6		298
1240	Molecular prognostic markers in locally advanced colon cancer. <b>2007</b> , 6, 683-90		45
1239	Exploring alternative individualized treatment strategies in colorectal cancer. <b>2007</b> , 7 Suppl 1, S28-36		5
1238	Type 2 diabetes mellitus and CA 19-9 levels. <b>2007</b> , 13, 5357-9		52
1237	Molecular profiling and risk stratification of adenocarcinoma of the colon. <b>2007</b> , 96, 693-703		37
1236	Pathology of colorectal cancer. <b>2007</b> , 19, 769-76		27
1235	The pancreatic cancer proteome - recent advances and future promise. <b>2007</b> , 1, 1066-79		13
1234	High-performance proteomics as a tool in biomarker discovery. <b>2007</b> , 7 Suppl 1, 18-26		30
1233	[Sentinel node biopsy in colorectal cancer. A multifunctional tool or a missing link?]. <b>2007</b> , 31, 279-80		
1232	Principaux marqueurs circulants utilisables en cancérologie. <b>2007</b> , 1, 9-17		
1231	Different roles of tumor marker monitoring after curative resections of gastric and colorectal cancers. <b>2008</b> , 53, 1537-43		9
1230	Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update. <b>2008</b> , 57, 759-75		48
1229	Imaging of primary and metastatic pancreatic cancer using a fluorophore-conjugated anti-CA19-9 antibody for surgical navigation. <i>World Journal of Surgery</i> , <b>2008</b> , 32, 1057-66	3-3	85
1228	Cachexia worsens prognosis in patients with resectable pancreatic cancer. <b>2008</b> , 12, 1193-201		260
1227	Fluorophore-conjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer. <b>2008</b> , 12, 1938-50		116
1226	Noninvasive diagnostic modalities for early detection of colorectal cancer. <b>2008</b> , 4, 24-33		1

1225	Individualization of therapy based on clinical and molecular parameters. <b>2008</b> , 4, 193-200	1
1224	Perspectives of tumour markers in gastrointestinal malignancies - an overview. <b>2008</b> , 70, 274-80	1
1223	Identification of patients with high-risk stage II colon cancer for adjuvant therapy. <b>2008</b> , 51, 503-7	176
1222	Colorectal carcinoma prognosis can be predicted by alterations in gene p53 exons 5 and 8. <b>2008</b> , 23, 581-6	20
1221	Identification and distribution of thioredoxin-like 2 as the antigen for the monoclonal antibody MC3 specific to colorectal cancer. <b>2008</b> , 8, 2220-9	17
1220	Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. <b>2008</b> , 8, 3051-60	76
1219	Analysis of the urine proteome in patients with pancreatic ductal adenocarcinoma. <b>2008</b> , 2, 1047-57	30
1218	Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer. <b>2008</b> , 123, 1941-9	34
1217	Analysis of high molecular mass proteins larger than 150 kDa using cyanogen bromide cleavage and conventional 2-DE. <b>2008</b> , 29, 4158-68	3
1216	Prognostic and predictive factors in colorectal cancer. <b>2008</b> , 61, 561-9	90
1215	National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. <b>2008</b> , 54, e11-79	451
1214	Requesting biochemical tumor markers: A costly gap between evidence and practice?. <b>2008</b> , 4, 157-160	1
1213	Marqueurs tumoraux: utilisation clinique en 2008 et avancées récentes. <b>2008</b> , 2008, 23-26	
1212	Targeted therapy of cancer: new roles for pathologists in colorectal cancer. <b>2008</b> , 21 Suppl 2, S23-30	41
1211	[Not Available]. <b>2008</b> , 145, 12S6-12S12	
1210	[Not Available]. <b>2008</b> , 145S4, 12S6-12S12	
1209	Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. <b>2008</b> , 8, 194	66
1208	Integrating chromosomal aberrations and gene expression profiles to dissect rectal tumorigenesis. <b>2008</b> , 8, 314	33

1207	Proteome analysis of membrane fractions in colorectal carcinomas by using 2D-DIGE saturation labeling. <b>2008</b> , 7, 4247-55		74
1206	Systemic treatment of colorectal cancer. <i>Gastroenterology</i> , <b>2008</b> , 134, 1296-310	13.3	364
1205	Application of a global proteomic approach to archival precursor lesions: deleted in malignant brain tumors 1 and tissue transglutaminase 2 are upregulated in pancreatic cancer precursors. <b>2008</b> , 8, 608-16		45
1204	Detection of microsatellite instability in colorectal cancer using an alternative multiplex assay of quasi-monomorphic mononucleotide markers. <b>2008</b> , 10, 154-9		32
1203	Genomics and proteomics in predicting cancer outcomes. <b>2008</b> , 17, 257-77, vii		5
1202	Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. <b>2008</b> , 263, 170-81		106
1201	P53 and bcl-2 in colorectal cancer arising in patients under 40 years of age: distribution and prognostic relevance. <b>2008</b> , 44, 1217-22		23
1200	CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. <b>2008</b> , 9, 132-8		181
1199	Microsatellite instability and the association with plasma homocysteine and thymidylate synthase in colorectal cancer. <b>2008</b> , 26, 583-9		10
1198	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5705-12	2.2	1358
1197	The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. <b>2008</b> , 19 Suppl 6, vi1-8		49
1196	Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. <b>2008</b> , 57, 941-50		251
1195	Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. <b>2008</b> , 68, 10315-23		103
1194	The essential role of the in situ immune reaction in human colorectal cancer. <b>2008</b> , 84, 981-7		84
1193	Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3681-6	2.2	69
1192	Early distant relapse after optimal local control in locally advanced rectal cancer. <b>2008</b> , 5, 18		2
1191	Simone's OncOpinion. <b>2008</b> , 30, 4		
1190	Simone's OncOpinion. <b>2008</b> , 30, 4		

1189 Biomarkers in Colorectal Cancer. **2008**, 30, 1-12

1188 Recent advances in the molecular diagnosis and prognosis of colorectal cancer. **2008**, 8, 277-88 47

1187 Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. **2008**, 98, 832-9 83

1186 Application of proteome analysis to the assessment of prognosis and response prediction in clinical oncology. **2008**, 8, 141-5 5

1185 Improving colorectal cancer management: the potential of proteomics. **2008**, 2, 253-89 7

1184 Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. **2008**, 14, 1413-7 95

1183 Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. **2008**, 19, 915-9 98

1182 Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspective. **2008**, 17, 519-27 11

1181 Pharmacoeigenomics in colorectal cancer: a step forward in predicting prognosis and treatment response. **2008**, 9, 1903-16 21

1180 [New approaches to early detection, estimation of prognosis and therapy for malignant tumours of the gastrointestinal tract]. **2008**, 46, 216-22 0

1179 Molecular medicine, gene-expression profiling and molecular diagnostics: putting the cart before the horse. **2008**, 2, 201-7 11

1178 Serum thymidine kinase 1 reflects the progression of pre-malignant and malignant tumors during therapy. **2008**, 1, 705-11 14

1177 Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments. **2008**, 20, 466-71 19

1176 Another Adventure. **2008**, 30, 3-4

1175 Proteomics of pancreatic cancer. **2008**, 36, 329-36 35

1174 [Prognostic role of KRAS mutation in colorectal cancer]. **2009**, 96 Suppl, S23-30 1

1173 Molecular Markers for Individualized Therapy in Colorectal Cancer: Progress Towards a Pharmacogenomics Array. **2009**, 7, 70-80

1172 Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. **2009**, 8, 2382-95 127

1171	Increased CA 19-9 level in patients without malignant disease. <b>2009</b> , 47, 750-4		49
1170	Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry. <b>2009</b> , 47, 713-23		28
1169	In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5944-51	2.2	666
1168	Limited value of CA 19-9 in predicting early treatment failure in patients with advanced pancreatic cancer. <b>2009</b> , 77, 140-6		7
1167	Expression of 5-fluorouracil-related enzymes in lung cancer: ELISA characterizes enzyme activity and messenger RNA expression. <b>2009</b> , 21, 1037-43		4
1166	Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer. <b>2009</b> , 48, 385-90		25
1165	Follow up your unexpected clinical observations!. <b>2009</b> , 48, 325-7		1
1164	Correlation between thymidylate synthase protein expression and gene polymorphism with clinicopathological parameters in colorectal carcinoma. <b>2009</b> , 17, 181-6		3
1163	A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. <b>2009</b> , 20, 239-43		39
1162	Colorectal carcinoma with extremely low CA19-9. <b>2009</b> , 2009, 780263		2
1161	Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients. <b>2009</b> , 5, 167-75		21
1160	Serum efficacy biomarkers for oncology. <b>2009</b> , 3, 47-54		2
1159	Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. <b>2009</b> , 20, 1223-9		379
1158	The prognostic significance of tryptophanyl-tRNA synthetase in colorectal cancer. <b>2009</b> , 18, 2949-56		57
1157	Use of archived specimens in evaluation of prognostic and predictive biomarkers. <b>2009</b> , 101, 1446-52		752
1156	The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. <b>2009</b> , 21, 665-74		140
1155	Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes. <b>2009</b> , 124, 1220-6		34
1154	Tumor border configuration added to TNM staging better stratifies stage II colorectal cancer patients into prognostic subgroups. <b>2009</b> , 115, 4021-9		38

1153	Integrative approach for prioritizing cancer genes in sporadic colon cancer. <b>2009</b> , 48, 953-62	42
1152	Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma. <b>2009</b> , 100, 546-52	10
1151	Prognostic significance of peritoneal tumour cells identified at surgery for colorectal cancer. <b>2009</b> , 96, 769-77	27
1150	MicroRNAs are novel biomarkers of colorectal cancer. <b>2009</b> , 96, 702-10	93
1149	Common gastric and colon (GC) carcinoma with an anomaly in the GC amylase (AMY) gene and good prognosis: clinical findings of common GC carcinoma. <b>2009</b> , 18, 29-37	
1148	Improved survival in an Asian cohort of young colorectal cancer patients: an analysis of 523 patients from a single institution. <b>2009</b> , 24, 1075-83	28
1147	Pancreatic cancer surveillance among high-risk populations: knowledge and intent. <b>2009</b> , 18, 229-38	16
1146	Staging, prognostic factors, and therapy of localized rectal cancer. <b>2009</b> , 11, 167-74	4
1145	CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. <b>2009</b> , 13, 349-53	42
1144	Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer. <b>2009</b> , 55, 564-75	27
1143	Clinical significance of tumor markers and an emerging perspective on colorectal cancer. <i>Cancer Science</i> , <b>2009</b> , 100, 195-9	6.9 79
1142	Genetic prognostic and predictive markers in colorectal cancer. <b>2009</b> , 9, 489-99	517
1141	Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. <b>2009</b> , 100, 266-73	288
1140	CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. <b>2009</b> , 101, 1162-7	33
1139	Preoperative investigations for metastatic staging of colon and rectal cancer across multiple centres--what is current practice?. <b>2009</b> , 11, 592-600	14
1138	Biomarkers in oncology: trials and tribulations. <b>2009</b> , 1180, 111-8	4
1137	A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ. <b>2009</b> , 73, 352-6	43
1136	Antigen choice in adoptive T-cell therapy of cancer. <b>2009</b> , 21, 190-9	36



1135	Carcinoembryonic antigen as a predictor of pathologic response and a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and surgery. <b>2009</b> , 74, 810-7		65
1134	Changes in cytokine and biomarker blood levels in patients with colorectal cancer during dendritic cell-based vaccination. <b>2009</b> , 48, 1157-64		21
1133	Pathologic response to preoperative therapy: does it mean what we think it means?. <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 1465-79	3.1	13
1132	Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection. <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 2516-23	3.1	18
1131	Pharmacogenomics and -genetics in colorectal cancer. <b>2009</b> , 61, 375-80		14
1130	Adjuvant therapy for colon cancer: present and perspectives. <b>2009</b> , 35, 160-6		38
1129	Xanthine oxidoreductase - clinical significance in colorectal cancer and in vitro expression of the protein in human colon cancer cells. <b>2009</b> , 45, 648-55		33
1128	Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. <b>2009</b> , 45, 1999-2006		76
1127	A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?. <b>2009</b> , 45, 1935-49		77
1126	An audit of tumour marker utilization in Greece. <b>2009</b> , 20, e66-9		13
1125	Significance of serum tumor markers carcinoembryonic antigen, CA 19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation. <b>2009</b> , 41, 682-4		16
1124	The irrepressible rise of biomarkers in oncology. <b>2009</b> , 57, 509-10		1
1123	uPA and PAI-1 in rectal cancer--relationship to radiotherapy and clinical outcome. <b>2009</b> , 153, 46-53		23
1122	Cystic seminoma with elevated value of carbohydrate antigen 19-9 in tumor fluid mimicking cystic teratoma. <b>2009</b> , 88, 1693-5		4
1121	Proteomic methodologies and their application in colorectal cancer research. <b>2009</b> , 46, 319-42		17
1120	Persistent elevation of serum CA 19-9 with no evidence of malignant disease. <b>2009</b> , 41, 357-63		42
1119	Improving colorectal cancer screening and care in the Veterans Affairs Healthcare system. <b>2009</b> , 8, 22-8		40
1118	Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. <b>2009</b> , 7, 105		44

1117	Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer. <b>2009</b> , 8, 142-8		36
1116	Pharmacogenetics and biomarkers in colorectal cancer. <b>2009</b> , 9, 147-60		19
1115	Chemotherapy, which drugs and when. <b>2009</b> , 45 Suppl 1, 50-6		15
1114	Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence. <b>2009</b> , 21, 565-9		59
1113	Clinical implications of microsatellite instability in sporadic colon cancers. <b>2009</b> , 21, 369-73		72
1112	Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma. <b>2009</b> , 38, 422-6		37
1111	The role of carcinoembryogenic antigen in predicting response and survival to neoadjuvant chemoradiotherapy for distal rectal cancer. <b>2009</b> , 52, 1137-43		89
1110	NCCN Clinical Practice Guidelines in Oncology: colon cancer. <b>2009</b> , 7, 778-831		325
1109	Marqueurs tumoraux et cancers du tractus gastro-intestinal. <b>2009</b> , 4, 1-12		
1108	An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer. <b>2010</b> , 24, 1645-52		5
1107	Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer. <b>2010</b> , 23, 1393-400		10
1106	Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 1010-23	3.1	33
1105	Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 2349-56	3.1	54
1104	Elevated tumour marker: an indication for imaging?. <b>2010</b> , 47, 327-30		2
1103	Systemic dysregulation of CEACAM1 in melanoma patients. <b>2010</b> , 59, 215-30		46
1102	Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings. <b>2010</b> , 15, 359-68		33
1101	Vers un traitement personnalisé du cancer colorectal: facteurs pronostiques et prédictifs. <b>2010</b> , 12, 584-592		
1100	Epidemiology, molecular changes, histopathology and diagnosis of colorectal cancer. <b>2010</b> , 42, 252-259		1

1099	Dermokine as a novel biomarker for early-stage colorectal cancer. <b>2010</b> , 45, 1201-11		25
1098	Biomarkers in colorectal cancer. <i>Clinical and Translational Oncology</i> , <b>2010</b> , 12, 261-70	3.6	1
1097	Ability of 18F-FDG PET/CT to diagnose recurrent colorectal cancer in patients with elevated CEA concentrations. <b>2010</b> , 24, 395-401		32
1096	Prevalence of positive FDG-PET findings in patients with high CEA levels. <b>2010</b> , 24, 433-9		5
1095	Microsatellite Status and Adjuvant Chemotherapy in Patients with Stage II Colon Cancer. <b>2010</b> , 6, 148-157		2
1094	Developing and sustaining quality improvement partnerships in the VA: the Colorectal Cancer Care Collaborative. <b>2010</b> , 25 Suppl 1, 38-43		40
1093	Molecular markers for early detection. <b>2010</b> , 37, 224-42		34
1092	Information technology solutions for integration of biomolecular and clinical data in the identification of new cancer biomarkers and targets for therapy. <b>2010</b> , 128, 488-98		10
1091	Data integration and exploration for the identification of molecular mechanisms in tumor-immune cells interaction. <b>2010</b> , 11 Suppl 1, S7		15
1090	The impact of a high-frequency microsatellite instability phenotype on the tumor location-related genetic differences in colorectal cancer. <b>2010</b> , 196, 133-9		9
1089	Screening and Verification of Differentially Expressed Proteins from Pancreatic Cancer Tissue. <b>2010</b> , 28, 884-890		2
1088	Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. <b>2010</b> , 127, 2569-75		87
1087	Does serum carcinoembryonic antigen elevation in patients with postoperative stage II colorectal cancer indicate recurrence? Comparison with stage III. <b>2010</b> , 102, 154-7		10
1086	Colorectal cancer proteomics, molecular characterization and biomarker discovery. <b>2010</b> , 4, 159-78		38
1085	Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel-assisted digestion and iTRAQ labeling mass spectrometry. <b>2010</b> , 277, 3028-38		48
1084	CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy. <b>2010</b> , 6, 98-105		30
1083	Plasma concentrations of VCAM-1 and PAI-1: a predictive biomarker for post-operative recurrence in colorectal cancer. <i>Cancer Science</i> , <b>2010</b> , 101, 1886-90	6.9	33
1082	Immune infiltration in human tumors: a prognostic factor that should not be ignored. <b>2010</b> , 29, 1093-102		725

1081	Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma. <b>2010</b> , 102, 1384-90		42
1080	Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer. <b>2010</b> , 103, 223-31		15
1079	KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. <b>2010</b> , 103, 1627-36		38
1078	Prostate cancer as a model for tumour immunotherapy. <b>2010</b> , 10, 580-93		272
1077	Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications. <i>Journal of Oncology</i> , <b>2010</b> , 2010, 392652	4-5	24
1076	Colonic Polyps and Colon Cancer. <b>2010</b> , 351-360		
1075	Biological and clinical markers in colorectal cancer: state of the art. <b>2010</b> , 2, 422-31		12
1074	Colorectal cancer detection by means of optical fluoroscopy. A study on 494 subjects. <b>2010</b> , 2, 694-700		6
1073	Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?. <b>2010</b> , 8, 73-88		1
1072	Biomarker-based prediction of response to therapy for colorectal cancer: current perspective. <b>2010</b> , 134, 478-90		60
1071	Combination therapy in high-risk stage II or stage III colon cancer: current practice and future prospects. <b>2010</b> , 2, 261-72		27
1070	A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. <b>2010</b> , 15, 699-731		121
1069	Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3937-44	2.2	231
1068	Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. <b>2010</b> , 194, 766-71		57
1067	American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 493-508	2.2	340
1066	miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. <b>2010</b> , 9, 2265-75		131
1065	Quality of nonmetastatic colorectal cancer care in the Department of Veterans Affairs. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3176-81	2.2	53
1064	Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. <b>2010</b> , 21, 441-447		250

1063	Combined analysis of survivin autoantibody and carcinoembryonic antigen biomarkers for improved detection of colorectal cancer. <b>2010</b> , 48, 719-25		15
1062	A combination of serum markers for the early detection of colorectal cancer. <b>2010</b> , 16, 6111-21		104
1061	Blood-based peptide, genetic, and epigenetic biomarkers for diagnosing gastrointestinal cancers. <b>2010</b> , 4, 459-71		1
1060	YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?. <i>Cancers</i> , <b>2010</b> , 2, 1453-91	6.6	49
1059	A novel prognostic index in colorectal cancer defined by serum carcinoembryonic antigen and plasma tissue inhibitor of metalloproteinases-1. <b>2010</b> , 45, 200-7		10
1058	The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. <b>2010</b> , 21, 1013-9		38
1057	Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival. <b>2010</b> , 145, 1177-83		32
1056	Multigene assays to improve assessment of recurrence risk and benefit from chemotherapy in early-stage colon cancer: has the time finally arrived, or are we still stage locked?. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3904-7	2.2	8
1055	Serum determination of CA 19-9 in diagnosing pancreatic cancer: an obituary. <b>2010</b> , 42, 73-4		7
1054	Acute right upper quadrant pain: a lesson in odds. <b>2010</b> , 42, 72-3		
1053	Alterations in glycosylation as biomarkers for cancer detection. <b>2010</b> , 63, 322-9		316
1052	KRAS mutation screening in colorectal cancer: From paper to practice. <b>2010</b> , 9, 22-30		16
1051	First alert for recurrence during follow-up after potentially curative resection for colorectal carcinoma: CA 19-9 should be included in surveillance programs. <b>2010</b> , 9, 48-51		13
1050	Integrating biomarkers into clinical decision making for colorectal cancer. <b>2010</b> , 9 Suppl 1, S16-27		6
1049	Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. <i>Gastroenterology</i> , <b>2010</b> , 138, 949-57.e1-7	13.3	227
1048	The chromosomal instability pathway in colon cancer. <i>Gastroenterology</i> , <b>2010</b> , 138, 2059-72	13.3	505
1047	[Recommendations for diagnosis, staging and treatment of pancreatic cancer (Part I). Grupo Español de Consenso en Cáncer de Páncreas]. <b>2010</b> , 134, 643-55		7
1046	Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study. <b>2010</b> , 95, 292-7		11

1045	Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study. <b>2010</b> , 46, 3323-31		39
1044	The next thing in prognostic molecular markers: microRNA signatures of cancer. <b>2010</b> , 59, 706-8		50
1043	[Recent developments of pharmacogenomics in the treatment of colorectal cancers]. <b>2010</b> , 68, 233-53		2
1042	Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. <b>2010</b> , 59, 1501-10		51
1041	American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3388-404	2.2	171
1040	Colorectal Cancer. <b>2010</b> , 457-476		
1039	Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy. <b>2010</b> , 15, 243-8		11
1038	Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 610-8	2.2	692
1037	Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 17-24	2.2	408
1036	C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. <b>2011</b> , 103, 689-97		119
1035	Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1261-70	2.2	489
1034	Microsatellite instability and colorectal cancer. <b>2011</b> , 135, 1269-77		92
1033	Genetic-based biomarkers and next-generation sequencing: the future of personalized care in colorectal cancer. <b>2011</b> , 8, 331-345		20
1032	Identification and validation of SRC and phospho-SRC family proteins in circulating mononuclear cells as novel biomarkers for pancreatic cancer. <b>2011</b> , 4, 83-91		18
1031	Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. <b>2011</b> , 105, 239-45		91
1030	Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. <b>2011</b> , 11, 617-34		78
1029	Gastrointestinal Oncology. <b>2011</b> ,		
1028	Cancer Systems Biology, Bioinformatics and Medicine. <b>2011</b> ,		3

1027	Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. <b>2011</b> , 155, 69-79		248
1026	Sperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicity. <b>2011</b> , 178, 1009-20		60
1025	Development of molecular biomarkers in individualized treatment of colorectal cancer. <b>2011</b> , 10, 279-89		22
1024	Biomarker-based selection of therapy for colorectal cancer. <b>2011</b> , 5, 319-32		12
1023	Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer. <b>2011</b> , 42, 1897-910		18
1022	Histologic characteristics of non-microsatellite-Instable colon adenomas correlate with distinct molecular patterns. <b>2011</b> , 42, 244-53		5
1021	Prediction of metastasis and recurrence in colorectal cancer based on gene expression analysis: ready for the clinic?. <i>Cancers</i> , <b>2011</b> , 3, 2858-69	6.6	21
1020	The value of molecular biomarkers in biliary tract cancer in the era of targeted therapy. <b>2011</b> , 1, 2-5		1
1019	Carbohydrate markers of pancreatic cancer. <b>2011</b> , 39, 340-3		18
1018	Analytical performance and clinical concordance of the cancer biomarkers CA 15-3, CA 19-9, CA 125 II, Carcinoembryonic Antigen, and Alpha-Fetoprotein on the Dimension Vista <sup>®</sup> System. <b>2011</b> , 44, 1128-1136		5
1017	C. 72-114		
1016	Dictionary. 1-54		
1015	Molecular Imaging and Metastasis. 516-537		
1014	Molecular diagnostics in pancreatic cancer. <b>2011</b> , 20-35		
1013	The state of contemporary molecular diagnostics of colorectal cancer. <b>2011</b> , 4, 229-233		
1012	Treatment of patients with colorectal cancer at a public hospital in Porto Alegre. <b>2011</b> , 31, 346-350		
1011	Stool and Blood Sampling for Early Detection of Colorectal Cancer. <b>2011</b> , 93-105		
1010	High expression of testes-specific protease 50 is associated with poor prognosis in colorectal carcinoma. <b>2011</b> , 6, e22203		28

1009	A 56-year-old man with a normal chest radiograph, elevated CA 19-9, and multiple hepatic lesions. <b>2011</b> , 18, 191-5		
1008	Bevacizumab in metastatic colorectal cancer and carcino-embryonic antigen kinetics: case report and review of literature. <b>2011</b> , 22 Suppl 2, S15-7		7
1007	SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. <b>2011</b> , 35, 937-48		183
1006	The role of carcinoembryonic antigen after neoadjuvant chemoradiotherapy in patients with rectal cancer. <b>2011</b> , 54, 245-52		47
1005	CA 19-9 level in patients with type 2 diabetes mellitus and its relation to the metabolic control and microvascular complications. <b>2011</b> , 341, 28-32		25
1004	NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. <b>2011</b> , 9 Suppl 5, S1-32; quiz S33		195
1003	Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer. <i>Cancer Science</i> , <b>2011</b> , 102, 1188-92	6.9	56
1002	Clinical significance of serum levels of immune-associated molecules, uric acid and soluble MHC class I chain-related molecules A and B, as diagnostic tumor markers for pancreatic ductal adenocarcinoma. <i>Cancer Science</i> , <b>2011</b> , 102, 1673-9	6.9	12
1001	Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients. <b>2011</b> , 104, 1000-6		18
1000	Tumor volume and percent positive lymph nodes as a predictor of 5-year survival in colorectal cancer. <b>2011</b> , 150, 649-55		15
999	Colon Cancer. <b>2011</b> , 325-377		
998	Identification of adipophilin as a potential plasma biomarker for colorectal cancer using label-free quantitative mass spectrometry and protein microarray. <b>2011</b> , 20, 2195-203		53
997	Accuracy of monitoring serum carcinoembryonic antigen levels in postoperative stage III colorectal cancer patients is limited to only the first postoperative year. <b>2011</b> , 41, 1357-62		9
996	Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. <i>Annals of Surgical Oncology</i> , <b>2011</b> , 18, 3694-700	3.1	45
995	Prognostic significance of preoperative bowel obstruction in stage III colorectal cancer. <i>Annals of Surgical Oncology</i> , <b>2011</b> , 18, 2432-41	3.1	32
994	Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. <i>Annals of Surgical Oncology</i> , <b>2011</b> , 18, 2461-8	3.1	87
993	Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. <i>Annals of Surgical Oncology</i> , <b>2011</b> , 18, 3271-7	3.1	39
992	Tumor immunosurveillance in human cancers. <b>2011</b> , 30, 5-12		123



991	Laparoscopic extraperitoneal rectal cancer surgery: the clinical practice guidelines of the European Association for Endoscopic Surgery (EAES). <b>2011</b> , 25, 2423-40		28
990	SMAD4 protein expression and cell proliferation in colorectal adenocarcinomas. <b>2011</b> , 459, 511-9		7
989	Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. <b>2011</b> , 137, 1379-96		24
988	Early postoperative CEA level is a better prognostic indicator than is preoperative CEA level in predicting prognosis of patients with curable colorectal cancer. <b>2011</b> , 26, 1135-41		70
987	Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (IFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting. <b>2011</b> , 68, 1017-26		4
986	The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. <b>2011</b> , 33, 335-40		82
985	Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain. <i>Clinical and Translational Oncology</i> , <b>2011</b> , 13, 798-804	3.6	4
984	Immune Cells in Colorectal Cancer: Prognostic Relevance and Role of MSI. <b>2011</b> , 4, 377-92		69
983	Predictive and prognostic biomarkers in colorectal cancer. <b>2011</b> , 6, 482-489		
982	Current treatment options for pancreatic carcinoma. <b>2011</b> , 13, 195-205		29
981	Genetic alterations of K-ras may reflect prognosis in stage III colon cancer patients below 60 years of age. <b>2011</b> , 103, 25-33		12
980	Heme oxygenase-1 germ line GTn promoter polymorphism is an independent prognosticator of tumor recurrence and survival in pancreatic cancer. <b>2011</b> , 104, 305-11		21
979	Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online. <b>2011</b> , 117, 4155-65		21
978	Soluble E-cadherin as a serum biomarker candidate: elevated levels in patients with late-stage colorectal carcinoma and FAP. <b>2011</b> , 128, 1384-92		35
977	Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer. <b>2011</b> , 128, 1935-45		16
976	Discovery of putative pancreatic cancer biomarkers using subcellular proteomics. <b>2011</b> , 74, 79-88		24
975	MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. <b>2011</b> , 17, 5812-21		130
974	[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. <b>2011</b> , 49, 461-531		204

973	Circulating antibodies to carcinoembryonic antigen related to improved recurrence-free survival of patients with colorectal carcinoma. <b>2011</b> , 39, 838-45	8	
972	Assessment of novel combinations of biomarkers for the detection of colorectal cancer. <b>2010</b> , 7, 123-32	21	
971	Liver Metastasis: Biology and Clinical Management. <b>2011</b> ,	3	
970	A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker. <b>2011</b> , 10, M111.009712	89	
969	Measurement of circulating cell-free DNA levels by a new simple fluorescent test in patients with primary colorectal cancer. <b>2011</b> , 135, 264-70	58	
968	Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer. <b>2011</b> , 22, 369-75	16	
967	microRNA-10b: a new marker or the marker of pancreatic ductal adenocarcinoma?. <b>2011</b> , 17, 5527-9	16	
966	Bending the cost curve in cancer care. <b>2011</b> , 364, 2060-5	311	
965	Serum biomarker panels for the detection of pancreatic cancer. <b>2011</b> , 17, 805-16	168	
964	Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. <b>2011</b> , 22, 1717-25	42	
963	Metastatic pancreatic cancer: what can nurses do?. <b>2011</b> , 15, 424-8	1	
962	Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals. <b>2011</b> , 46, 60-9	60	
961	Screening for colorectal cancer: possible improvements by risk assessment evaluation?. <b>2011</b> , 46, 1283-94	22	
960	Prognostic value of colorectal cancer biomarkers. <i>Cancers</i> , <b>2011</b> , 3, 2080-105	6.6	3
959	Development of a serum biomarker assay that differentiates tumor-associated MUC5AC (NPC-1C ANTIGEN) from normal MUC5AC. <b>2011</b> , 2011, 934757	13	
958	Biomarkers in advanced colorectal cancer: challenges in translating clinical research into practice. <i>Cancers</i> , <b>2011</b> , 3, 1844-60	6.6	1
957	LAP+CD4+ T cells are suppressors accumulated in the tumor sites and associated with the progression of colorectal cancer. <b>2012</b> , 18, 5224-33	15	
956	Evaluation of predictive markers for patients with advanced colorectal cancer. <b>2012</b> , 51, 849-59	35	

955	Serum CA19-9 level associated with metabolic control and pancreatic beta cell function in diabetic patients. <b>2012</b> , 2012, 745189		19
954	Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. <b>2012</b> , 18, 530-8		85
953	Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers. <b>2012</b> , 18, 609-13		11
952	Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers. <b>2012</b> , 50, 721-5		14
951	Intermittent androgen suppression for rising PSA level. <b>2012</b> , 367, 2252; author reply 2252-3		2
950	Relationship between CA 19-9 levels and glucose regulation in a middle-aged and elderly Chinese population. <b>2012</b> , 4, 147-52		14
949	Elevated preoperative CEA is associated with worse survival in stage I-III rectal cancer patients. <b>2012</b> , 107, 266-74		42
948	American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1715-24	2.2	433
947	Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer. <b>2012</b> , 106, 133-40		36
946	The prognostic importance of miR-21 in stage II colon cancer: a population-based study. <b>2012</b> , 107, 1169-74		73
945	Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome. <b>2012</b> , 8, e24s-30s		12
944	Molecular pathology of pancreatic cancer: from bench-to-bedside translation. <b>2012</b> , 13, 744-52		26
943	Moderne adjuvante Chemotherapie und Nachsorge. <b>2012</b> , 15, 58-65		
942	Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer. <b>2012</b> , 256, 763-71; discussion 771		60
941	Practice parameters for the management of colon cancer. <b>2012</b> , 55, 831-43		114
940	Rectal cancer. <b>2012</b> , 10, 1528-64		127
939	Autoimmune cholangitis and cholangiocarcinoma. <b>2012</b> , 27, 1783-9		9
938	Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs). <b>2012</b> , 11, 5556-63		13

937	Identification of EFEMP2 as a serum biomarker for the early detection of colorectal cancer with lectin affinity capture assisted secretome analysis of cultured fresh tissues. <b>2012</b> , 11, 3281-94		44
936	ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. <b>2012</b> , 61, 1560-7		139
935	An optimized predictor panel for colorectal cancer diagnosis based on the combination of tumor-associated antigens obtained from protein and phage microarrays. <b>2012</b> , 75, 4647-55		41
934	Response prediction in metastasised colorectal cancer using intratumoural thymidylate synthase: results of a randomised multicentre trial. <b>2012</b> , 48, 1443-51		12
933	Aberrant promoter methylation of beta-1,4 galactosyltransferase 1 as potential cancer-specific biomarker of colorectal tumors. <b>2012</b> , 51, 1133-43		18
932	Cancer classification using the Immunoscore: a worldwide task force. <b>2012</b> , 10, 205		538
931	Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. <i>Cancer Science</i> , <b>2012</b> , 103, 1714-21	6.9	36
930	Colorectal Cancer. <b>2012</b> , 86-136		
929	CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab. <b>2012</b> , 30, 65-71		31
928	First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). <b>2012</b> , 41, 1213-20		51
927	Sodium chloride vs. sodium bicarbonate for the prevention of contrast medium-induced nephropathy: a randomized controlled trial. <b>2012</b> , 33, 2071-9		70
926	Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. <b>2012</b> , 13, 817-26		281
925	Cancer biomarkers. <b>2012</b> , 6, 140-6		394
924	Comparative analysis of tumor markers and evaluation of their predictive value in patients with colorectal cancer. <b>2012</b> , 35, 108-13		4
923	Potential Role of KRAS and Other Mutations in the Adjuvant Therapy of Colorectal Cancer. <b>2012</b> , 8, 192-203		
922	Clinical Implications of Circulating Tumor Cells in Advanced Colorectal Cancer. <b>2012</b> , 8, 233-242		
921	Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis. <b>2012</b> , 27, 1333-8		37
920	Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. <i>Annals of Surgical Oncology</i> , <b>2012</b> , 19, 2471-6	3.1	18

919	Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer--five microRNAs in a prognostic index. <i>World Journal of Surgery</i> , <b>2012</b> , 36, 2699-707	3-3	73
918	Contemporary Coloproctology. <b>2012</b> ,		6
917	Designs for Clinical Trials. <b>2012</b> ,		3
916	Serum metabolomic profile as a means to distinguish stage of colorectal cancer. <b>2012</b> , 4, 42		81
915	The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA. <b>2012</b> , 7, e36412		20
914	ALCAM (CD166) expression and serum levels in pancreatic cancer. <b>2012</b> , 7, e39018		31
913	Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. <b>2012</b> , 7, e46000		136
912	Reversible high blood CEA and CA19-9 concentrations in a diabetic patient. <b>2012</b> , 7,		5
911	Follow Up and Recurrence of Colorectal Cancer. <b>2012</b> ,		
910	Assessing the clinical significance of tumor markers in common neoplasms. <b>2012</b> , 4, 2558-78		8
909	Elevation of CA 125 and CA 19-9 in patients with end-stage liver disease. <b>2012</b> , 27, e147-51		10
908	The immune score as a new possible approach for the classification of cancer. <b>2012</b> , 10, 1		455
907	Bridging the gap: moving predictive and prognostic assays from research to clinical use. <b>2012</b> , 18, 1531-9		33
906	Prognostic role of methylated free circulating DNA in colorectal cancer. <b>2012</b> , 131, 2308-19		73
905	B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer. <b>2012</b> , 131, 2528-36		69
904	Prognostic value of plasmatic tumor M2 pyruvate kinase and carcinoembryonic antigen in the survival of colorectal cancer patients. <b>2012</b> , 33, 825-32		7
903	A man with Klinefelter's syndrome and new abdominal distension: a discussion of evaluation and management. <b>2012</b> , 43, 314-8		1
902	A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels. <b>2012</b> , 8, 172-9		2

901	Individuals at high-risk for pancreatic cancer development: management options and the role of surgery. <b>2012</b> , 21, e49-58		5
900	Usefulness of transcription-reverse transcription concerted reaction method for detecting circulating tumor cells in patients with colorectal cancer. <i>Annals of Surgical Oncology</i> , <b>2012</b> , 19, 2060-5	3.1	19
899	Methylation status in patients with early stage colon cancer: a new prognostic marker?. <b>2012</b> , 130, 488-9		9
898	Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site. <b>2012</b> , 33, 463-74		40
897	Regulation of carcinoembryonic antigen release from colorectal cancer cells. <b>2012</b> , 39, 3695-704		18
896	Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery. <b>2013</b> , 8, 43		46
895	Evaluation of a CLEIA automated assay system for the detection of a panel of tumor markers. <b>2013</b> , 34, 3093-100		17
894	Biomarkers for predicting future metastasis of human gastrointestinal tumors. <b>2013</b> , 70, 3631-56		26
893	iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance. <b>2013</b> , 108, 1846-53		50
892	Serum tumor markers and PET/CT imaging for tumor recurrence detection. <b>2013</b> , 27, 97-104		9
891	Alternatives for the intensive follow-up after curative resection of colorectal cancer. Potential novel biomarkers for the recommendations. <i>Pathology and Oncology Research</i> , <b>2013</b> , 19, 619-29	2.6	2
890	Detection of resectable recurrences in colorectal cancer patients with 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography. <b>2013</b> , 28, 479-87		12
889	Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer. <b>2013</b> , 30, 155-65		8
888	Elevated preoperative carcinoembryonic antigen (CEA) and Ki67 is predictor of decreased survival in IIA stage colon cancer. <i>World Journal of Surgery</i> , <b>2013</b> , 37, 208-13	3.3	33
887	Preoperative elevation of carcinoembryonic antigen predicts poor tumor response and frequent distant recurrence for patients with rectal cancer who receive preoperative chemoradiotherapy and total mesorectal excision: a multi-institutional analysis in an Asian population. <b>2013</b> , 28, 511-7		23
886	Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer. <b>2013</b> , 46, 1453-61		37
885	Rapid decline to normal levels of extraordinarily elevated CA 19-9 after Giardiasis. <b>2013</b> , 37, e97		1
884	Immunoassay of nine serological tumor markers on a hydrogel-based microchip. <b>2013</b> , 39, 619-628		7

883 Ovarian Neoplasm Imaging. **2013**,

882 Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. **2013**, 34, 3279-92 76

881 Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912. **2013**, 24, 2560-2565 35

880 Molecular Pathology of Neoplastic Gastrointestinal Diseases. **2013**, 2

879 Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. **2013**, 13, 416 59

878 Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9. **2013**, 13, 404 39

877 Elevation of preoperative s-CEA concentration in stage IIA colorectal cancer can also be a high risk factor for stage II patients. *Annals of Surgical Oncology*, **2013**, 20, 2914-20 3.1 16

876 For biliary dilatation, a negative endosonography needs additional image studies in weight loss suggesting malignancy. **2013**, 58, 2345-52 3

875 Re: CA 19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and preoperative therapy. *Annals of Surgical Oncology*, **2013**, 20, 2108-10 3.1 5

874 Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls. **2013**, 13, 554 39

873 CA 19-9: handle with care. **2013**, 51, 1369-83 59

872 Biomarkers in Oncology. **2013**, 1

871 Pitfalls in Tumor Markers Testing. **2013**, 177-193

870 The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer. **2013**, 133, 1408-18 39

869 Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women. *Gastroenterology*, **2013**, 145, 348-56.e1-2 13.3 45

868 Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis. **2013**, 13, 581-99 46

867 Kallikrein-related peptidase 4 (KLK4) mRNA predicts short-term relapse in colorectal adenocarcinoma patients. **2013**, 330, 106-12 28

866 Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. *Journal of Clinical Oncology*, **2013**, 31, 759-65 2.2 189

865	The long journey of cancer biomarkers from the bench to the clinic. <b>2013</b> , 59, 147-57	107
864	KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib. <b>2013</b> , 49, 2424-32	10
863	Predictors of response in locally advanced rectal cancer following concurrent chemoradiotherapy. <b>2013</b> , 5, 18-22	1
862	Free circulating DNA as a biomarker of colorectal cancer. <b>2013</b> , 11 Suppl 1, S54-7	11
861	Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. <b>2013</b> , 108, 1316-23	49
860	Tumor markers in clinical practice: a review focusing on common solid cancers. <b>2013</b> , 22, 4-11	146
859	Transient therapy-related surge in serum tumor biomarkers: characterizing behavior and postulating its biologic role. <b>2013</b> , 86, 15-22	12
858	Early detection of recurrence after curative resection for colorectal cancer - obstacles when using soluble biomarkers?. <b>2013</b> , 48, 326-33	3
857	CA19.9 antigen circulating in the serum of colon cancer patients: where is it from?. <b>2013</b> , 45, 792-7	19
856	Molecular markers in pancreatic cancer diagnosis. <b>2013</b> , 418, 22-9	24
855	Strategies for discovering novel pancreatic cancer biomarkers. <b>2013</b> , 81, 126-34	40
854	Physician follow-up and observation of guidelines in the post treatment surveillance of colorectal cancer. <b>2013</b> , 154, 244-55	18
853	Macrophage inflammatory protein-3 alpha (MIP-3a) is a novel serum prognostic marker in patients with colorectal cancer. <b>2013</b> , 107, 160-6	19
852	Molecular markers in colorectal cancer: clinical relevance in stage II colon cancer. <b>2013</b> , 2, 243-263	4
851	Diagnostic use of epitope detection in monocytes blood test for early detection of colon cancer metastasis. <b>2013</b> , 9, 605-9	9
850	The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates. <b>2013</b> , 13, 340-351	13
849	Medullary thyroid cancer secreting carbohydrate antigen 19-9 (Ca 19-9): a fatal case report. <b>2013</b> , 98, 3550-4	20
848	Novel diagnostic and prognostic biomarkers in biliary tract cancer. <b>2013</b> , 7, 487-99	5



847	Prognostic role of serum AZGP1, PEDF and PRDX2 in colorectal cancer patients. <i>Carcinogenesis</i> , <b>2013</b> , 34, 1265-72	4.6	40
846	Factors Influencing Survival in Stage IV Colorectal Cancer: The Influence of DNA Ploidy. <b>2013</b> , 2013, 490578		10
845	Prognostic Significance of DR-70 Levels in Dysplastic Colorectal Polyps. <b>2013</b> , 2013, 275392		5
844	MicroRNA-21 in colorectal cancer: "Just another brick in the wall"?. <b>2013</b> , 105, 840-1		2
843	Good news for "Alice": height and sex differences in cancer risk. <b>2013</b> , 105, 841-3		3
842	In-depth characterization of the secretome of colorectal cancer metastatic cells identifies key proteins in cell adhesion, migration, and invasion. <b>2013</b> , 12, 1602-20		82
841	The prognostic value of the apoptosis pathway in colorectal cancer: a review of the literature on biomarkers identified by immunohistochemistry. <b>2013</b> , 5, 13-29		53
840	Biomarkers in precision therapy in colorectal cancer. <b>2013</b> , 1, 166-83		69
839	Clinical significance and prognostic value of pentraxin-3 as serologic biomarker for lung cancer. <b>2013</b> , 14, 4215-21		14
838	Prediction of recurrence and survival in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3+ regulatory T cells. <b>2013</b> , 6, 594-602		38
837	Usefulness of MALDI-TOF/MS identification of low-MW fragments in sera for the differential diagnosis of pancreatic cancer. <b>2013</b> , 42, 622-32		14
836	Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer. <b>2013</b> , 42, 740-59		22
835	Clinical validity of tissue carcinoembryonic antigen expression as ancillary to serum carcinoembryonic antigen concentration in patients curatively resected for colorectal cancer. <b>2013</b> , 15, e503-11		12
834	PRECLINOMICS. <b>2013</b> , 131-162		
833	The advantage of circulating tumor cells over serum carcinoembryonic antigen for predicting treatment responses in rectal cancer. <b>2013</b> , 9, 1489-500		14
832	Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer. <b>2013</b> , 108, 791-7		60
831	An Unusual Presentation of Isolated Leptomeningeal Disease in Carcinoma of Unknown Primary With Pancreatic Features. <b>2013</b> , 1, 2324709613494830		6
830	Impact of 18F-FDG-PET/CT on treatment strategy in colorectal cancer lung metastasis before lung radiofrequency ablation. <b>2013</b> , 34, 689-93		6

829	Screening for pancreatic cancer: why, how, and who?. <b>2013</b> , 257, 17-26	147
828	Practice parameters for the management of rectal cancer (revised). <b>2013</b> , 56, 535-50	294
827	Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. <b>2013</b> , 257, 1053-8	89
826	Colorectal cancer biomarkers and the potential role of cancer stem cells. <b>2013</b> , 4, 241-50	61
825	MicroRNA-21 as a potential colon and rectal cancer biomarker. <b>2013</b> , 19, 5615-21	55
824	Identification of high-risk factors as indicators for adjuvant therapy in stage II colon cancer patients treated at a single institution. <b>2013</b> , 6, 659-666	8
823	Usefulness of carcinoembryonic antigen for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer. <b>2013</b> , 54, 116-22	10
822	Tissue inhibitor of metalloproteinases-1 as a biological marker in colorectal cancer: influence of smoking on plasma levels?. <b>2013</b> , 28, 226-30	1
821	Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution. <b>2013</b> , 8, e78977	31
820	Reappraisal of Pretreatment Carcinoembryonic Antigen in Patients with Rectal Cancer Receiving Preoperative Chemoradiotherapy. <b>2013</b> , 99, 93-99	8
819	The clinical significance of preoperative serum levels of carbohydrate antigen 19-9 in colorectal cancer. <b>2013</b> , 84, 231-7	18
818	. <b>2013</b> ,	
817	What is the Role of Surveillance for Colorectal Cancer?. <b>2014</b> , 261-271	
816	The diagnostics of colorectal cancer. <b>2014</b> , 18, 1-6	42
815	Discovery of tumor markers for gastric cancer by proteomics. <b>2014</b> , 9, e84158	30
814	A systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of colorectal cancer. <b>2014</b> , 9, e103910	42
813	Diagnostic significance of TIMP-1 level in serum and its immunohistochemical expression in colorectal cancer patients. <b>2014</b> , 65, 296-304	9
812	Neoadjuvant therapy for pancreas cancer: past lessons and future therapies. <b>2014</b> , 20, 15564-79	37

811	Rising CEA levels in a patient with colon carcinoma: metachronous medullary thyroid cancer. <b>2014</b> , 29, e184-6	4
810	Colonoscopy and carcinoembryonic antigen variations. <b>2014</b> , 51, 69-72	2
809	Methodical and pre-analytical characteristics of a multiplex cancer biomarker immunoassay. <b>2014</b> , 4, 219-31	10
808	. <b>2014</b> ,	4
807	Pancreatic and ovarian cancer biomarkers. <b>2014</b> , 759-770	0
806	Evaluation of preoperative serum markers for individual patient prognosis in stage I-III rectal cancer. <b>2014</b> , 35, 10237-48	32
805	TroVax in colorectal cancer. <b>2014</b> , 10, 3196-200	14
804	Blood CEA levels for detecting recurrent colorectal cancer. <b>2014</b> ,	2
803	CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. <b>2014</b> , 6, 1571-84	63
802	Epigenetic inactivation of the novel candidate tumor suppressor gene ITIH5 in colon cancer predicts unfavorable overall survival in the CpG island methylator phenotype. <b>2014</b> , 9, 1290-301	24
801	The role of adjuvant chemotherapy in stage II colorectal cancer patients. <b>2014</b> , 29, 1237-43	22
800	Borealin/Dasra B is overexpressed in colorectal cancers and contributes to proliferation of cancer cells. <b>2014</b> , 31, 248	17
799	Analysis of stage and clinical/prognostic factors for colon and rectal cancer from SEER registries: AJCC and collaborative stage data collection system. <b>2014</b> , 120 Suppl 23, 3793-806	47
798	Detection of colorectal cancer by DNA methylation biomarker SEPT9: past, present and future. <b>2014</b> , 8, 755-69	30
797	Trends in laboratory test volumes for Medicare Part B reimbursements, 2000-2010. <b>2014</b> , 138, 189-203	25
796	Positron emission tomography/computed tomography for optimized colon cancer staging and follow up. <b>2014</b> , 49, 191-201	20
795	Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens. <i>Cancers</i> , <b>2014</b> , 6, 1753-68	6.6 13
794	Aberrant glycosylation as biomarker for cancer: focus on CD43. <b>2014</b> , 2014, 742831	72

793	Tumour markers and kidney function: a systematic review. <b>2014</b> , 2014, 647541	34
792	Transcriptional profiling of peripheral blood in pancreatic adenocarcinoma patients identifies diagnostic biomarkers. <b>2014</b> , 59, 2714-20	19
791	Determinants of recurrence after intended curative resection for colorectal cancer. <b>2014</b> , 49, 1399-408	15
790	Serpin B5 is a CEA-interacting biomarker for colorectal cancer. <b>2014</b> , 134, 1595-604	23
789	Role of micro-RNA in colorectal cancer screening. <b>2014</b> , 92, 654-8	7
788	Tumor markers CEA and CA 19-9 correlate with radiological imaging in metastatic colorectal cancer patients receiving first-line chemotherapy. <b>2014</b> , 35, 10121-7	14
787	The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy. <b>2014</b> , 23, 394-400	16
786	An epidemiology-based model to estimate the rate of inappropriateness of tumor marker requests. <b>2014</b> , 52, 889-97	5
785	Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. <b>2014</b> , 6, 22-33	83
784	CA 19-9 as a Serum Biomarker in Cancer. <b>2014</b> , 1-19	
783	Colorectal Cancer Circulating Biomarkers. <b>2014</b> , 1-21	3
782	Evolving role of gene expression signatures as biomarkers in early-stage colon cancer. <b>2014</b> , 45, 399-404	8
781	Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis. <b>2014</b> , 14, 976	50
780	Serum levels of preoperative $\alpha$ -fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation. <b>2014</b> , 26, 553-61	10
779	Spatiotemporal proteomic analyses during pancreas cancer progression identifies serine/threonine stress kinase 4 (STK4) as a novel candidate biomarker for early stage disease. <b>2014</b> , 13, 3484-96	18
778	Molecular Diagnostics of Pancreatic Cancer. <b>2014</b> , 259-282	
777	Significance of the serum carcinoembryonic antigen level during the follow-up of patients with completely resected non-small-cell lung cancer. <b>2014</b> , 45, 687-92	9
776	Immunoguiding, the Final Frontier in the Immunotherapy of Cancer. <b>2014</b> , 37-51	

775	Prognostic value of pretreatment level of carcinoembryonic antigen on tumour downstaging and early occurring metastasis in locally advanced rectal cancer following neoadjuvant radiotherapy (30 Gy in 10 fractions). <b>2014</b> , 16, 33-9		12
774	What to do for the incidental pancreatic cystic lesion?. <b>2014</b> , 23, 117-25		18
773	Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. <b>2014</b> , 134, 2513-22		214
772	Post-Resection Surveillance in GI Cancers. <b>2014</b> , 76, 382-91		
771	Elevation in multiple serum inflammatory biomarkers predicts survival of pancreatic cancer patients with inoperable disease. <b>2014</b> , 45, 161-7		13
770	Déterminants moléculaires et génétiques d'efficacité et de toxicité du 5-fluoro-uracile. <b>2014</b> , 16, 91-95		
769	Intensity of follow-up after pancreatic cancer resection. <i>Annals of Surgical Oncology</i> , <b>2014</b> , 21, 747-51	3.1	37
768	CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy. <b>2014</b> , 73, 409-16		18
767	Tissue-based biomarkers predicting outcomes in metastatic colorectal cancer: a review. <i>Clinical and Translational Oncology</i> , <b>2014</b> , 16, 425-35	3.6	14
766	Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients. <b>2014</b> , 8, 679-88		29
765	MicroRNA biomarkers in whole blood for detection of pancreatic cancer. <b>2014</b> , 311, 392-404		315
764	Cancer Immunotherapy Meets Oncology. <b>2014</b> ,		
763	Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. <b>2014</b> , 95, 269-80		53
762	Proteomics in investigation of cancer metastasis: functional and clinical consequences and methodological challenges. <b>2014</b> , 14, 426-40		10
761	'Toxgnostics': an unmet need in cancer medicine. <b>2014</b> , 14, 440-5		24
760	Clinical relevance of KRAS mutations in codon 13: Where are we?. <b>2014</b> , 343, 1-5		21
759	Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma. <b>2014</b> , 35, 4673-85		28
758	Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation. <b>2014</b> , 20, 11-28		48

757	When to perform a pancreatoduodenectomy in the absence of positive histology? A consensus statement by the International Study Group of Pancreatic Surgery. <b>2014</b> , 155, 887-92		89
756	Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling. <b>2014</b> , 99, 26-39		74
755	EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. <b>2014</b> , 50, 1.e1-1.e34		274
754	Role of Micro-RNA in Colorectal Cancer Screening. <b>2014</b> , 92, 654-658		0
753	Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer. <b>2014</b> , 110, 2081-9		58
752	Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. <b>2014</b> , 110, 2935-44		63
751	A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile. <b>2014</b> , 109, 1942-52		80
750	CA 19-9 as a marker in addition to CEA to monitor colorectal cancer. <b>2014</b> , 13, 239-44		69
749	Update on the management of cholangiocarcinoma. <b>2014</b> , 32, 570-8		23
748	Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. <b>2014</b> , 20, 5787-95		91
747	The 9-bp deletion at position 8272 in region V of mitochondrial DNA is associated with renal cell carcinoma outcome. <b>2016</b> , 27, 1973-5		4
746	[Diagnostic capability of carcinoembryonic antigen elevation]. <b>2014</b> , 37, 551-7		2
745	Progress against GI cancer during the American Society of Clinical Oncology's first 50 years. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1521-30	2.2	33
744	KLK11 mRNA expression predicts poor disease-free and overall survival in colorectal adenocarcinoma patients. <b>2014</b> , 8, 671-85		23
743	Prognostic value of preoperative D-dimer and carcinoembryonic antigen levels in patients undergoing intended curative resection for colorectal cancer: a prospective cohort study. <b>2014</b> , 29, 1427-32		18
742	Screening for pancreatic cancer. <b>2014</b> , 48, 115-36		17
741	Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma. <b>2014</b> , 14, 578		67
740	Elevated serum CA 19-9 at screening tests: underlying conditions and role of abdominopelvic CT. <b>2014</b> , 24, 2435-48		2

739	Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer. <b>2014</b> , 32, 904-12		68
738	Carcinoembryonic antigen expression level as a predictive factor for response to 5-fluorouracil in colorectal cancer. <b>2014</b> , 41, 459-66		23
737	Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors. <i>Annals of Surgical Oncology</i> , <b>2014</b> , 21 Suppl 4, S680-6	3.1	47
736	Recent advances in personalized colorectal cancer research. <b>2014</b> , 347, 15-21		44
735	Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. <b>2014</b> , 232, 199-209		882
734	The clinical utility of biomarkers in the management of pancreatic adenocarcinoma. <b>2014</b> , 24, 67-76		12
733	Clinical implication of elevated CA 19-9 level and the relationship with glucose control state in patients with type 2 diabetes. <b>2014</b> , 46, 249-55		11
732	The role of RCAS1 as a biomarker in diagnosing CRC and monitoring tumor recurrence and metastasis. <b>2014</b> , 35, 6149-57		3
731	MicroRNAs as novel biomarkers for pancreatic cancer diagnosis: a meta-analysis based on 18 articles. <b>2014</b> , 35, 8837-48		18
730	Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. <b>2014</b> , 13, 114		44
729	Assessment of the value of carcinoembryonic antigen reduction ratio as a prognosis factor in rectal cancer. <b>2014</b> , 208, 99-105		13
728	Discovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers using high density antibody arrays. <b>2014</b> , 96, 291-9		48
727	Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow-up study. <b>2014</b> , 67, 454-61		33
726	9. Pancreatic lipase. <b>2014</b> , 153-180		0
725	Noninvasive Early Markers in Gallbladder Cancer. <b>2014</b> , 379-406		
724	The effect of glycemic control on CEA, CA 19-9, amylase and lipase levels. <b>2015</b> , 10, 8-13		6
723	Toxgnostics: predicting and preventing chemotherapy-induced side effects. <b>2014</b> , 11, 683-685		
722	A preoperative serum signature of CEA+/CA125+/CA19-9 $\geq$ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. <b>2015</b> , 136, 2216-27		71

721	Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-All isoforms. <b>2015</b> , 5, 15921	51
720	Diagnosis and Staging of Pancreatic Malignancies. <b>2015</b> , 351-413	
719	Prediction of colorectal cancer diagnosis based on circulating plasma proteins. <b>2015</b> , 7, 1166-78	68
718	Guideline familiarity predicts variation in self-reported use of routine surveillance PET/CT by physicians who treat head and neck cancer. <b>2015</b> , 13, 69-77	22
717	Non-invasive prognostic protein biomarker signatures associated with colorectal cancer. <b>2015</b> , 7, 1153-65	40
716	Preoperative carcinoembryonic antigen and prognosis of colorectal cancer. An independent prognostic factor still reliable. <b>2015</b> , 100, 617-25	15
715	Diagnostic value of (18)F-FDG PET/CT as first choice in the detection of recurrent colorectal cancer due to rising CEA. <b>2015</b> , 15, 11	23
714	A General Cutoff Level Combined With Personalized Dynamic Change of Serum Carcinoembryonic Antigen Can Suggest Timely Use of FDG PET for Early Detection of Recurrent Colorectal Cancer. <b>2015</b> , 40, e465-9	7
713	Elevated CA19-9 as the Most Significant Prognostic Factor in Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiotherapy. <b>2015</b> , 94, e1793	18
712	Blood CEA levels for detecting recurrent colorectal cancer. <b>2015</b> , CD011134	85
711	Determination of Effective Factors on Survival of GI Cancers: Results of Five Years Follow up in Iranian Population. <b>2015</b> , 8, 256-66	3
710	Preoperative serum CA125 is an independent predictor for prognosis in operable patients with non-small cell lung cancer. <b>2015</b> , 62, 602-9	8
709	An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer. <b>2015</b> , 6, 32561-74	32
708	Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer. <b>2015</b> , 9, 1247-55	19
707	Circulating RNAs as new biomarkers for detecting pancreatic cancer. <b>2015</b> , 21, 8527-40	105
706	Circulating Oxidized Low-Density Lipoproteins and Antibodies against Oxidized Low-Density Lipoproteins as Potential Biomarkers of Colorectal Cancer. <b>2015</b> , 2015, 146819	5
705	A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma. <b>2015</b> , 2015, 587250	20
704	Small Bowel Adenocarcinoma as the Cause of Gastrointestinal Bleeding in Celiac Disease: A Rare Malignancy in a Common Disease. <b>2015</b> , 2015, 865383	1



703	Novel blood-based microRNA biomarkers for diagnosis of pancreatic cancer: a meta-analysis. <b>2015</b> , 101, 199-205	1
702	Colorectal Cancer Biomarkers: Where Are We Now?. <b>2015</b> , 2015, 149014	111
701	Adnexal masses in the premenopausal patient. <b>2015</b> , 58, 47-52	4
700	Stage-specific frequency and prognostic significance of aneuploidy in patients with sporadic colorectal cancer--a meta-analysis and current overview. <b>2015</b> , 30, 1015-28	10
699	Carbohydrate antigen 19-9 is a useful prognostic marker in esophagogastric junction adenocarcinoma. <b>2015</b> , 4, 1659-66	14
698	. <b>2015</b> ,	
697	Genetic or non-genetic prognostic factors in colon cancer. <b>2015</b> ,	
696	microRNAs in the Malignant Transformation Process. <b>2015</b> , 889, 1-21	4
695	Pancreatic Cancer. <b>2015</b> , 343-392	
694	Surveillance and Survivorship after Treatment for Colon Cancer. <b>2015</b> , 28, 262-70	4
693	Diagnostic evaluation and staging of pancreatic ductal adenocarcinoma. <b>2015</b> , 42, 19-27	34
692	Elevated levels of 14-3-3 proteins, serotonin, gamma enolase and pyruvate kinase identified in clinical samples from patients diagnosed with colorectal cancer. <b>2015</b> , 441, 133-41	26
691	Evaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic cancer. <b>2015</b> , 15, 34-9	15
690	Biomarkers for early diagnosis of pancreatic cancer. <b>2015</b> , 9, 305-15	29
689	Patterns of circulating tumor cells identified by CEP8, CK and CD45 in pancreatic cancer. <b>2015</b> , 136, 1228-33	70
688	Positive postoperative CEA is a strong predictor of recurrence for patients after resection for colorectal liver metastases. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 3087-93	3.1 29
687	Clinicopathologic features and oncologic outcomes of colorectal cancer patients with extremely high carcinoembryonic antigen. <b>2015</b> , 30, 63-9	5
686	Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. <b>2015</b> , 113, 268-74	58

685	Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma. <b>2015</b> , 16, 1136-9		
684	Elevation of Pretreatment Carcinoembryonic Antigen Level as a Prognostic Factor for Colon Cancer: Incorporating a C Stage in the AJCC TNM Classification. <b>2015</b> , 150, 755-6		3
683	Detection of miRNA as non-invasive biomarkers of colorectal cancer. <b>2015</b> , 16, 2810-23		55
682	Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. <b>2015</b> , 523, 177-82		1678
681	Salivary microRNAs show potential as a noninvasive biomarker for detecting resectable pancreatic cancer. <b>2015</b> , 8, 165-73		88
680	Intensified follow-up in colorectal cancer patients using frequent Carcino-Embryonic Antigen (CEA) measurements and CEA-triggered imaging: Results of the randomized "CEAwatch" trial. <b>2015</b> , 41, 1188-96		51
679	Fluorescence Imaging for Surgeons. <b>2015</b> ,		7
678	Biomarkers and Molecular Imaging as Predictors of Response to Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer. <b>2015</b> , 14, 227-38		28
677	Hepatic hemangioma masquerading as a tumor originating from the stomach. <b>2015</b> , 9, 1406-1408		3
676	Assessment of DNA Integrity, Applications for Cancer Research. <b>2015</b> , 70, 197-246		30
675	An elevated preoperative serum carbohydrate antigen 19-9 level is a significant predictor for peritoneal dissemination and poor survival in colorectal cancer. <b>2015</b> , 17, 417-25		21
674	Carcinoembryonic antigen as a cancer screening marker by primary care physicians. <b>2015</b> , 215, 191-2		
673	Personalized treatment for patients with colorectal cancer: role of biomarkers. <b>2015</b> , 9, 337-47		18
672	Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy. <b>2015</b> , 15, 156		72
671	CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 1315-23	3.1	10
670	Concordance of Carcinoembryonic Antigen Ratio and Response Evaluation Criteria in Solid Tumors as Prognostic Surrogate Indicators of Metastatic Colorectal Cancer Patients Treated with Chemotherapy. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 2262-8	3.1	22
669	Biomarkers as Prognostic, Predictive, and Surrogate Endpoints. <b>2015</b> , 31-41		1
668	Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer. <b>2015</b> , 21, 1764-71		38

667	Preoperative serum markers for individual patient prognosis in stage I-III colon cancer. <b>2015</b> , 36, 7897-906	26
666	Utility of postoperative CEA for surveillance of recurrence after resection of primary colorectal cancer. <b>2015</b> , 16, 123-128	38
665	The Microbiome and Cancer: Is the 'Oncobiome' Mirage Real?. <b>2015</b> , 1, 24-35	51
664	Anastomotic leakage after curative rectal cancer resection has no impact on long-term survival: a propensity score analysis. <b>2015</b> , 30, 1667-75	19
663	Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. <b>2015</b> , 34, 86	107
662	The accuracy of circulating microRNA-21 in the diagnosis of colorectal cancer: a systematic review and meta-analysis. <b>2015</b> , 17, 0100-7	11
661	Mathematical framework for activity-based cancer biomarkers. <b>2015</b> , 112, 12627-32	29
660	Glycosylation in cancer: mechanisms and clinical implications. <b>2015</b> , 15, 540-55	1405
659	Carcinoembryonic antigen has prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study of KROG 14-12. <b>2015</b> , 116, 202-8	23
658	Automatic Immunoscoring of Immunohistochemistry Images of Human Lung Cancer Tissue Samples: A Screening Tool. <b>2015</b> ,	
657	[Terminology changes in serum tumor markers]. <b>2015</b> , 38, 565	
656	Esophageal cancer management: preoperative CA19.9 and CEA serum levels may identify occult advanced adenocarcinoma. <i>World Journal of Surgery</i> , <b>2015</b> , 39, 424-32	3-3 18
655	Molecular markers for colon diagnosis, prognosis and targeted therapy. <b>2015</b> , 111, 96-102	38
654	Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus. <b>2016</b> , 204, 419-22	13
653	Important molecular genetic markers of colorectal cancer. <b>2016</b> , 7, 53959-53983	75
652	Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. <b>2016</b> , 22, 1745-55	193
651	The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. <b>2016</b> , 7, E45-51	22
650	RAS and BRAF in metastatic colorectal cancer management. <b>2016</b> , 7, 687-704	39

649	Diagnostic Value of Methylated Septin9 for Colorectal Cancer Screening: A Meta-Analysis. <b>2016</b> , 22, 3409-3418	19
648	Disease Biomarkers in Gastrointestinal Malignancies. <b>2016</b> , 2016, 4714910	2
647	Cost-Effectiveness between Double and Single Fecal Immunochemical Test(s) in a Mass Colorectal Cancer Screening. <b>2016</b> , 2016, 6830713	3
646	Clinically Meaningful Use of Blood Tumor Markers in Oncology. <b>2016</b> , 2016, 9795269	37
645	Glycomic Approaches for the Discovery of Targets in Gastrointestinal Cancer. <i>Frontiers in Oncology</i> , <b>2016</b> , 6, 55	5-3 37
644	The Genome-Wide Analysis of Carcinoembryonic Antigen Signaling by Colorectal Cancer Cells Using RNA Sequencing. <b>2016</b> , 11, e0161256	11
643	Non-invasive biomarkers in pancreatic cancer diagnosis: what we need versus what we have. <b>2016</b> , 4, 134	60
642	Clinical Impact of Structured Follow-up After Pancreatic Surgery. <b>2016</b> , 45, 895-9	25
641	Survival analysis of veteran patients with pancreatic cancer. <b>2016</b> , 17, 399-407	5
640	Translating colorectal cancer genetics into clinically useful biomarkers. <b>2016</b> , 18, 749-62	4
639	Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling. <b>2016</b> , 139, 1821-9	18
638	Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study. <b>2016</b> , 91, 127-34	1
637	Predictive Value of Carcinoembryonic and Carbohydrate Antigen 19-9 Related to Some Clinical, Endoscopic and Histological Colorectal Cancer Characteristics. <b>2016</b> , 35, 324-332	5
636	Colonic Polyps and Colorectal Cancer. <b>2016</b> , 349-356	
635	Time to lowest postoperative carcinoembryonic antigen level is predictive on survival outcome in rectal cancer. <b>2016</b> , 6, 34131	5
634	Serum Metabolite Profiling for the Detection of Pancreatic Cancer: Results of a Large Independent Validation Study. <b>2016</b> , 45, 1418-1423	18
633	Serum tumor markers not useful in screening patients with pancreatic mucinous cystic lesions associated with malignant changes. <b>2016</b> , 15, 553-557	7
632	Relation between Carcinoembryonic Antigen Levels in Colon Cancer Tissue and Serum Carcinoembryonic Antigen Levels at Initial Surgery and Recurrence. <b>2016</b> , 91, 85-9	17

631	Colon Cancer: Preoperative Evaluation and Staging. <b>2016</b> , 433-442		
630	CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). <b>2016</b> , 27, 1565-72		20
629	Prognostic Significance of Preoperative Serum Carbohydrate Antigen 19-9 in Patients With Stage IV Colorectal Cancer. <b>2016</b> , 15, e157-e163		10
628	The endoscopist's role in the diagnosis and management of pancreatic cancer. <b>2016</b> , 10, 1027-39		1
627	Circulating Tumor Cells and Circulating Tumor DNA in Colorectal Cancer. <b>2016</b> , 1, 181-194		1
626	In Response to "Serum Tumor Marker Use in Patients With Advanced Solid Tumors". <b>2016</b> , 12, 273-4		4
625	High preoperative serum CA19-9 level is predictive of poor prognosis for patients with colorectal liver oligometastases undergoing hepatic resection. <b>2016</b> , 33, 121		18
624	A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer. <b>2016</b> , 5, 2763-2772		58
623	Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein $\alpha$ -chain (C4BPA) by quantitative proteomic analysis using tandem mass tags. <b>2016</b> , 115, 949-956		41
622	Can serum dynamics of carcinoembryonic antigen level during neoadjuvant chemoradiotherapy in rectal cancer predict tumor response and recurrence? A multi-institutional retrospective study. <b>2016</b> , 31, 1595-601		9
621	The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer. <b>2016</b> , 139, 2312-24		23
620	Plasma protein profiling in a stage defined pancreatic cancer cohort - Implications for early diagnosis. <b>2016</b> , 10, 1305-16		19
619	Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer. <i>Cancer Science</i> , <b>2016</b> , 107, 936-43	6.9	62
618	Mass spectrometry based translational proteomics for biomarker discovery and application in colorectal cancer. <b>2016</b> , 10, 503-15		13
617	Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research. <b>2016</b> , 55, 1273-1280		35
616	Clinical Implications and Future Perspectives of Circulating Tumor Cells and Biomarkers in Clinical Outcomes of Colorectal Cancer. <b>2016</b> , 9, 340-7		26
615	Postoperative carcinoembryonic antigen level has a prognostic value for distant metastasis and survival in rectal cancer patients who receive preoperative chemoradiotherapy and curative surgery: a retrospective multi-institutional analysis. <b>2016</b> , 33, 809-816		7
614	Systems medicine in colorectal cancer: from a mathematical model toward a new type of clinical trial. <b>2016</b> , 8, 314-36		6

- 613 Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen. **2016**, 29, 196-204 9
- 612 Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis. **2016**, 39, 1716-1722 41
- 611 Colorectal cancer. **2016**, 1-24
- 610 Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9  $\geq 1,000$  U/mL. **2016**, 6, 19222 22
- 609 Potential usefulness of apolipoprotein A2 isoforms for screening and risk stratification of pancreatic cancer. **2016**, 10, 1197-1207 16
- 608 The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care. **2016**, 9, 861-886 37
- 607 Carcinoembryonic Antigen Clearance Rate May Be a Prognostic Indicator for Metastatic Colorectal Cancer Patients Receiving Chemotherapy. **2016**, 101, 510-516
- 606 Potential role of microRNA-126 in the diagnosis of cancers: A systematic review and meta-analysis. **2016**, 95, e4644 7
- 605 Value of serum CA 19-9 in obstructive jaundice. **2016**, 6, 54-60
- 604 Clinical effectiveness of cancer screening biomarker tests offered as self-pay health service: a systematic review. **2016**, 26, 498-505 3
- 603 Detection of Biomarkers with Solid-Phase Proximity Ligation Assay in Patients with Colorectal Cancer. **2016**, 9, 251-5 4
- 602 Prognosis Can Be Predicted More Accurately Using Pre- and Postchemoradiotherapy Carcinoembryonic Antigen Levels Compared to Only Prechemoradiotherapy Carcinoembryonic Antigen Level in Locally Advanced Rectal Cancer Patients Who Received Neoadjuvant Chemoradiotherapy. **2016**, 95, e2215 6
- 601 Advances in adjuvant therapy of colon cancer. **2016**, 27, 204-212
- 600 Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. **2016**, 44, 698-711 602
- 599 Fluorophore-conjugated antibodies for imaging and resection of GI tumors. **2016**,
- 598 The promise of protein glycosylation for personalised medicine. **2016**, 1860, 1583-95 60
- 597 Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. **2016**, 4, 419-30 172
- 596 Blood expression of matrix metalloproteinases 8 and 9 and of their inducers S100A8 and S100A9 supports diagnosis and prognosis of PDAC-associated diabetes mellitus. **2016**, 456, 24-30 13

595	Intestinal Polyposis Syndromes. <b>2016,</b>	2
594	Clinicopathological significance of vascular endothelial growth factor, thymidine phosphorylase and microvessel density in colorectal cancer. <b>2016, 13, 1551-7</b>	8
593	Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. <b>2016, 22, 1734-1743</b>	58
592	An epidemiology-based model as a tool to monitor the outbreak of inappropriateness in tumor marker requests: a national scale study. <b>2016, 54, 473-82</b>	12
591	CA11-19: a tumor marker for the detection of colorectal cancer. <b>2016, 83, 545-51</b>	10
590	Protein glycosylation in gastric and colorectal cancers: Toward cancer detection and targeted therapeutics. <b>2017, 387, 32-45</b>	41
589	Transient elevation in serum carcinoembryonic antigen while on adjuvant chemotherapy for colon cancer: Is this of prognostic importance?. <b>2017, 13, e124-e131</b>	4
588	Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer. <b>2017, 40, 21-26</b>	3
587	Targeted Proteomics for Multiplexed Verification of Markers of Colorectal Tumorigenesis. <b>2017, 16, 407-427</b>	29
586	Serum and tissue markers in colorectal cancer: State of art. <b>2017, 111, 103-116</b>	19
585	Novel anticarcinoembryonic antigen antibody-drug conjugate has antitumor activity in the existence of soluble antigen. <b>2017, 6, 798-808</b>	8
584	Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples for Diagnosis and Treatment Monitoring. <b>2017, 1,</b>	210
583	Coptisine from Rhizoma Coptidis Suppresses HCT-116 Cells-related Tumor Growth in vitro and in vivo. <b>2017, 7, 38524</b>	35
582	Monitoring of Serum Carcinoembryonic Antigen Levels after Curative Resection of Colon Cancer: Cutoff Values Determined according to Preoperative Levels Enhance the Diagnostic Accuracy for Recurrence. <b>2017, 92, 276-282</b>	27
581	Incorporation of serum carcinoembryonic antigen levels into the prognostic grouping system of colon cancer. <b>2017, 32, 821-829</b>	10
580	Can protein science solve the unmet needs in pancreatic cancer diagnosis and therapy?. <b>2017, 14, 469-471</b>	
579	Molecular Diagnostics in Cancer. <b>2017, 1-14</b>	2
578	Diagnostic Biomarkers. <b>2017, 1-22</b>	

577	Specific microRNA-mRNA Regulatory Network of Colon Cancer Invasion Mediated by Tissue Kallikrein-Related Peptidase 6. <b>2017</b> , 19, 396-411		22
576	miR-15a-5p, A Novel Prognostic Biomarker, Predicting Recurrent Colorectal Adenocarcinoma. <b>2017</b> , 21, 453-464		33
575	E-cadherin: A potential biomarker of colorectal cancer prognosis. <b>2017</b> , 13, 4571-4576		46
574	Pancreatology. <b>2017</b> ,		
573	Whole liver CT texture analysis to predict the development of colorectal liver metastases-A multicentre study. <b>2017</b> , 92, 64-71		22
572	Pancreatic ductal adenocarcinoma: metastatic disease. <i>Clinical and Translational Oncology</i> , <b>2017</b> , 19, 1423-1429	3.6	7
571	CEA. <b>2017</b> , 143-155		
570	Association of Adjuvant Chemotherapy With Survival in Patients With Stage II or III Gastric Cancer. <b>2017</b> , 152, e171087		56
569	Prognostic value of immunoscore to identify mortality outcomes in adults with HBV-related primary hepatocellular carcinoma. <b>2017</b> , 96, e6735		18
568	Prognostic and Predictive Biomarkers for Colorectal Cancer. <b>2017</b> , 151-162		0
567	Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy. <b>2017</b> , 7, 45194		51
566	In situ memory T cells and patterns of invasion predict outcome in patients with early-stage oral squamous cell carcinoma. <b>2017</b> , 19, 199-205		4
565	Lymph Node Ratio as a Risk Factor for Recurrence After Adjuvant Chemotherapy in Stage III Colorectal Cancer. <b>2017</b> , 21, 867-878		8
564	Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy. <b>2017</b> , 23, 5074-5081		89
563	Use of Tumor Markers in Gastrointestinal Cancers: Surgeon Perceptions and Cost-Benefit Trade-Off Analysis. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 1165-1173	3.1	23
562	Elevated expression of miR-24-3p is a potentially adverse prognostic factor in colorectal adenocarcinoma. <b>2017</b> , 50, 285-292		27
561	Upregulated miR-16 expression is an independent indicator of relapse and poor overall survival of colorectal adenocarcinoma patients. <b>2017</b> , 55, 737-747		25
560	Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. <i>Clinical and Translational Oncology</i> , <b>2017</b> , 19, 667-681	3.6	18



559	Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients. <b>2017</b> , 140, 1888-1898	62
558	New developments in the early diagnosis of pancreatic cancer. <b>2017</b> , 11, 149-156	17
557	Cytotoxic T Cells and Granzyme B Associated with Improved Colorectal Cancer Survival in a Prospective Cohort of Older Women. <b>2017</b> , 26, 622-631	35
556	CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer. <b>2017</b> , 12, 787-794	4
555	Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients. <b>2017</b> , 218-219, 51-57	10
554	The potential of liquid biopsies for the early detection of cancer. <b>2017</b> , 1, 36	82
553	Cell-Free Circulating DNA Integrity Based on Peripheral Blood as a Biomarker for Diagnosis of Cancer: A Systematic Review. <b>2017</b> , 26, 1595-1602	25
552	Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. <b>2017</b> , 9,	137
551	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. <b>2017</b> , 114, 10202-10207	303
550	Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes. <b>2017</b> , 116, 969-982	48
549	Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy. <b>2017</b> , 22, 1069-1075	5
548	Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons. <b>2017</b> , 87, 987-992	26
547	Direct detection of early-stage cancers using circulating tumor DNA. <b>2017</b> , 9,	537
546	Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis. <b>2017</b> , 1868, 394-403	36
545	Selected reaction monitoring approach for validating peptide biomarkers. <b>2017</b> , 114, 13519-13524	15
544	Functionalized vertical GaN micro pillar arrays with high signal-to-background ratio for detection and analysis of proteins secreted from breast tumor cells. <b>2017</b> , 7, 14917	3
543	A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline. <b>2017</b> , 117, 1846-1854	51
542	Circulating exosomal miR-125a-3p as a novel biomarker for early-stage colon cancer. <b>2017</b> , 7, 4150	102

541	Melanoma arising in an ovarian cystic teratoma: a systematic review of presentation, treatment, and outcomes. <b>2017</b> , 296, 397-404		4
540	Colorectal Cancer in India: An Audit from a Tertiary Center in a Low Prevalence Area. <b>2017</b> , 8, 484-490		85
539	Circulating nucleosomes as new blood-based biomarkers for detection of colorectal cancer. <b>2017</b> , 9, 53		44
538	A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study. <b>2017</b> , 112, 172-183		72
537	Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 227-235	3.1	28
536	[Persistent elevation of Ca 19-9 and an unexpected finding. A case report]. <b>2017</b> , 85, 449-453		1
535	Persistent elevation of Ca 19-9 and an unexpected finding. A case report. <b>2017</b> , 85, 449-453		0
534	Pancreatic Cancer. <b>2017</b> , 367-377		
533	Cancer Biomarkers: Important Tools for Cancer Diagnosis and Prognosis. <b>2017</b> , 1-29		0
532	The future of immunocapture-capillary electrophoresis-high resolution mass spectrometry. <b>2017</b> , 9, 1627-1631		2
531	Correlation Between Preoperative Serum Carcinoembryonic Antigen Levels and Expression on Pancreatic and Rectal Cancer Tissue. <b>2017</b> , 9, 1179299X17710016		8
530	Proteins are potent biomarkers to detect colon cancer progression. <b>2017</b> , 24, 1212-1221		16
529	Plasma Mesothelin as a Novel Diagnostic and Prognostic Biomarker in Colorectal Cancer. <b>2017</b> , 8, 1355-1361		10
528	Development and Validation of a Serum Biomarker Panel for the Detection of Esophageal Squamous Cell Carcinoma through RNA Transcriptome Sequencing. <b>2017</b> , 8, 2346-2355		10
527	Serum CEA and CA 19-9 Levels are Associated with the Presence and Severity of Colorectal Neoplasia. <b>2017</b> , 58, 918-924		23
526	Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis. <b>2017</b> , 10, 4591-4598		56
525	Selectin Ligands Sialyl-Lewis a and Sialyl-Lewis x in Gastrointestinal Cancers. <b>2017</b> , 6,		55
524	Changes of MicroRNA Levels in Plasma of Patients with Rectal Cancer during Chemoradiotherapy. <b>2017</b> , 18,		10

523	Colorectal Cancer Blood-Based Biomarkers. <b>2017</b> , 2017, 2195361	26
522	Recent advances of bispecific antibodies in solid tumors. <b>2017</b> , 10, 155	89
521	The small vesicular culprits: the investigation of extracellular vesicles as new targets for cancer treatment. <b>2017</b> , 6, 45	24
520	Xanthogranulomatous Pancreatitis -A Rare Case Defying Clinical, Radiological and Tumor Marker Diagnostics with a Review of Literature. <b>2019</b> , 35, 144-150	1
519	CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5 (carcinoembryonic antigen)). <b>2017</b> ,	
518	Exosomal microRNAs derived from colorectal cancer-associated fibroblasts: role in driving cancer progression. <b>2017</b> , 9, 2666-2694	84
517	The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy. <b>2017</b> , 8, 1410-1416	5
516	Sex differences and effects of oestrogen in rat gastric mucosal defence. <b>2017</b> , 23, 426-436	12
515	Effect of the Multiple Intravenous Administration of Cultured Human Autologous Adipose-Derived Stem Cells on Tumor Biomarker Levels. <b>2017</b> , 7,	
514	Serum CA19-9 as a marker of circulating tumor cells in first reflux blood of colorectal cancer patients. <b>2017</b> , 8, 67918-67932	8
513	Adjuvant Chemotherapy for Stage II Colon Cancer: A Clinical Dilemma. <b>2017</b> , 13, 233-241	83
512	The tumour-stroma ratio in colon cancer: the biological role and its prognostic impact. <b>2018</b> , 73, 197-206	52
511	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <b>2018</b> , 142, 1242-1253	72
510	Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. <b>2018</b> , 105, 658-662	14
509	Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?. <b>2018</b> , 57, 750-758	5
508	Postoperative CEA is a better prognostic marker than CA19-9, hCGβr TATI after resection of colorectal liver metastases. <b>2018</b> , 40, 1010428317752944	11
507	Relations of Changes in Serum Carcinoembryonic Antigen Levels before and after Neoadjuvant Chemoradiotherapy and after Surgery to Histologic Response and Outcomes in Patients with Locally Advanced Rectal Cancer. <b>2018</b> , 94, 167-175	8
506	Carcinoembryonic Antigen-Still More to Learn From the Real World. <b>2018</b> , 4, 315-316	4

505	Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. <b>2018</b> , 4, 309-315	79	
504	Progression of Chronic Pancreatitis to Pancreatic Cancer: Is There a Role of Gene Mutations as a Screening Tool?. <b>2018</b> , 47, 227-232	7	
503	Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review). <b>2018</b> , 39, 2455-2472	46	
502	Intraplatelet Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor: New Biomarkers in Carcinoembryonic Antigen-Negative Colorectal Cancer?. <b>2018</b> , 5, 32-37	7	
501	Diagnostic Biomarkers. <b>2018</b> , 659-680	4	
500	Secondary Screening for Inherited Pancreatic Ductal Adenocarcinoma. <b>2018</b> , 1401-1434		
499	Development of Novel Diagnostic Pancreatic Tumor Biomarkers. <b>2018</b> , 1241-1272	1	
498	Glycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasis. <b>2018</b> , 333, 46-57	88	
497	Cancer glycan epitopes: biosynthesis, structure and function. <b>2018</b> , 28, 670-696	30	
496	Protein and glycomic plasma markers for early detection of adenoma and colon cancer. <b>2018</b> , 67, 473-484	39	
495	The association between clinical outcome and CD8 lymphocytic infiltration in advanced stages of colorectal cancer differs by latent virus infection in tumour tissue. <b>2018</b> , 72, 201-215		
494	Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer. <b>2018</b> , 72, 391-404	12	
493	Common and Uncommon Benign Pancreatic Lesions Mimicking Malignancy: Imaging Update and Review. <b>2018</b> , 39, 206-219	5	
492	Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma. <b>2018</b> , 43, 505-513	11	
491	Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. <b>2018</b> , 13, 134-138	15	
490	Design, expression and evaluation of novel chimeric protein constructed from colorectal tumor-associated antigen. <b>2018</b> , 119, 3464-3473	0	
489	The role of vitamin D in hepatic metastases from colorectal cancer. <i>Clinical and Translational Oncology</i> , <b>2018</b> , 20, 259-273	3.6	1
488	Extensive screening of microRNA populations identifies hsa-miR-375 and hsa-miR-133a-3p as selective markers for human rectal and colon cancer. <b>2018</b> , 9, 27256-27267		14

487	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1631-1641	2.2	448
486	Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2887-2894	2.2	76
485	Biomarkers in colorectal cancer: Current clinical utility and future perspectives. <i>World Journal of Clinical Cases</i> , <b>2018</b> , 6, 869-881	1.6	73
484	Proteomics Profiling of Pancreatic Cancer and Pancreatitis for Biomarkers Discovery. <b>2018</b> , 9,		3
483	Verification of the methodology for evaluating tumor-infiltrating lymphocytes in colorectal cancer. <b>2018</b> , 9, 15180-15197		9
482	[Conventional serum tumor markers in liver cancer. Retrospective analysis of 118 patients]. <b>2018</b> , 146, 1422-1428		1
481	Immunoscore-has it scored for colon cancer precision medicine?. <b>2018</b> , 6, S23		6
480	MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside. <b>2018</b> , 24, 2949-2973		93
479	The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients. <b>2018</b> , 18, 1076		7
478	Endoscopic Ultrasound in Pancreatic Cancer. <b>2018</b> ,		
477	The Levels of Tumor Markers in Pancreatic Neuroendocrine Carcinoma and Their Values in Differentiation Between Pancreatic Neuroendocrine Carcinoma and Pancreatic Ductal Adenocarcinoma. <b>2018</b> , 47, 1290-1295		6
476	Establishment of inflammation biomarkers-based nomograms to predict prognosis of advanced colorectal cancer patients based on real world data. <b>2018</b> , 13, e0208547		9
475	Combination of carcinoembryonic antigen with the American Joint Committee on Cancer TNM staging system in rectal cancer: a real-world and large population-based study. <b>2018</b> , 11, 5827-5834		8
474	The role of tissue and serum carcinoembryonic antigen in stages I to III of colorectal cancer-A retrospective cohort study. <b>2018</b> , 7, 5327-5338		22
473	Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5-fluorouracil- and oxaliplatin-based preoperative chemotherapy for liver metastases. <b>2018</b> , 9, 3-10		1
472	Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cells. <b>2018</b> , 143, 1963-1977		12
471	Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA. <b>2018</b> , 40, 1010428318776169		39
470	A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma. <b>2018</b> , 2018, 1863535		10

469	The clinical application of tumor markers in the screening of malignancies and interstitial lung disease of dermatomyositis/polymyositis patients: A retrospective study. <b>2018</b> , 6, 2050312118781895	11
468	High expression of ALDOA and DDX5 are associated with poor prognosis in human colorectal cancer. <b>2018</b> , 10, 1799-1806	21
467	Diagnostic Value of Methylated for Colorectal Cancer Detection. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 247	5:3 28
466	Intensity-modulated radiotherapy with systemic chemotherapy improves survival in patients with nonmetastatic unresectable pancreatic adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study. <b>2018</b> , 129, 326-332	18
465	Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway. <b>2018</b> , 37, 6041-6053	22
464	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <b>2018</b> , 391, 2128-2139	910
463	LIFR promotes tumor angiogenesis by up-regulating IL-8 levels in colorectal cancer. <b>2018</b> , 1864, 2769-2784	15
462	Association between infection and tumor markers: an observational retrospective study. <b>2018</b> , 8, e022374	2
461	Cancer Cell Glycocalyx and Its Significance in Cancer Progression. <b>2018</b> , 19,	29
460	The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer. <b>2018</b> , 2018, 5389820	30
459	Measurement of serum PODXL concentration for detection of pancreatic cancer. <b>2018</b> , 11, 1433-1445	5
458	Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. <b>2018</b> , 118, 1609-1616	31
457	Improving the accuracy of pancreatic cancer clinical staging by exploitation of nanoparticle-blood interactions: A pilot study. <b>2018</b> , 18, 661-665	10
456	Genetic and Epigenetic Modifications in Pancreatic Cancer. <b>2018</b> , 117-140	
455	Circulating Hybrid Cells Join the Fray of Circulating Cellular Biomarkers. <b>2019</b> , 8, 595-607	10
454	Pitfalls in testing for common tumor markers. <b>2019</b> , 191-211	2
453	Biosensors for early diagnosis of pancreatic cancer: a review. <b>2019</b> , 213, 67-89	40
452	Gangliosides profiling in serum of breast cancer patient: GM3 as a potential diagnostic biomarker. <b>2019</b> , 36, 419-428	16

451	Methylated Septin 9 and Carcinoembryonic Antigen for Serological Diagnosis and Monitoring of Patients with Colorectal Cancer After Surgery. <b>2019</b> , 9, 10326		14
450	Plasma microRNA Levels Combined with CEA and CA19-9 in the Follow-Up of Colorectal Cancer Patients. <i>Cancers</i> , <b>2019</b> , 11,	6.6	20
449	Unrecognized Value of Carcinoembryonic Antigen in Recurrent Rectal and Sigmoid Colon Cancer: Case Series. <b>2019</b> , 23,		2
448	Evaluation of the diagnostic ability of laminin gene family for pancreatic ductal adenocarcinoma. <b>2019</b> , 11, 3679-3703		14
447	Plasma circular RNA panel acts as a novel diagnostic biomarker for colorectal cancer. <b>2019</b> , 74, 60-68		45
446	Loss of Circulating Exosomal miR-92b is a Novel Biomarker of Colorectal Cancer at Early Stage. <b>2019</b> , 16, 1231-1237		19
445	Serum Expression of -Catenin Is a Potential Detection Marker in Patients with Colorectal Cancer. <b>2019</b> , 2019, 5070524		3
444	Increase in Carbohydrate Antigen 19-9 Levels without Tumor Progression after Polaprezinc Administration that Induced Deep Vein Thrombosis in a Colon Cancer Patient. <b>2019</b> , 64, 163-166		1
443	Diagnostic and Prognostic Value of Hypermethylation and Its Clinical Significance as a Novel Circulating Cell-Free DNA Biomarker in Colorectal Cancer. <i>Cancers</i> , <b>2019</b> , 11,	6.6	18
442	Deciphering DNA methylation signatures of pancreatic cancer and pancreatitis. <b>2019</b> , 11, 132		21
441	Diagnosis and Management of Pancreatic Adenocarcinoma in the Background of Chronic Pancreatitis: Core Issues. <b>2019</b> , 37, 315-324		14
440	CA19-9 elevation as an indication to start salvage treatment in surveillance after pancreatic cancer resection. <b>2019</b> , 19, 302-306		8
439	Impact of intramural and extramural vascular invasion on stage II-III colon cancer outcomes. <b>2019</b> , 119, 749-757		19
438	Metal-organic framework-based affinity materials in proteomics. <b>2019</b> , 411, 1745-1759		27
437	Glycosylation and glycan interactions can serve as extracellular machinery facilitating clathrin-independent endocytosis. <b>2019</b> , 20, 295-300		13
436	Biomarkers of Pancreatic Cancer. <b>2019</b> , 97-104		
435	Release of volatile organic compounds (VOCs) from colorectal cancer cell line LS174T. <b>2019</b> , 581, 113340		5
434	Role of Tumor Markers. <b>2019</b> , 233-244		

433	Biomarkers in Cancer Therapy. <b>2019</b> ,	1
432	Cystatin F as a key family 2 cystatin subunit and prognostic biomarker for early-stage pancreatic ductal adenocarcinoma. <b>2019</b> , 42, 79-90	4
431	A Novel Blood-Based Colorectal Cancer Diagnostic Technology Using Electrical Detection of Colon Cancer Secreted Protein-2. <b>2019</b> , 6, 1802115	16
430	Case 18-2019: A 24-Year-Old Woman with a Pelvic Mass. <b>2019</b> , 380, 2361-2369	
429	Tumor Markers in GI and HPB Cancers. <b>2019</b> , 139-154	
428	ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. <b>2019</b> , 30, 1232-1243	256
427	Protein functionalised self assembled monolayer based biosensor for colon cancer detection. <b>2019</b> , 201, 465-473	22
426	Molecular Imaging with Positron Emission Tomography. <b>2019</b> , 437-483	
425	Molecular Diagnostics in Colorectal Cancer. <b>2019</b> , 143-155	1
424	Heart myxoma develops oncogenic and metastatic phenotype. <b>2019</b> , 145, 1283-1295	7
423	Recent Advances in Liquid Biopsy in Precision Oncology Research. <b>2019</b> , 42, 337-342	20
422	Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: A pilot study. <b>2019</b> , 24, 335-342	13
421	High preoperative serum CA 19-9 levels can predict poor oncologic outcomes in colorectal cancer patients on propensity score analysis. <b>2019</b> , 96, 107-115	10
420	Evaluating the Guiding Role of Elevated Pretreatment Serum Carcinoembryonic Antigen Levels for Adjuvant Chemotherapy in Stage IIA Colon Cancer: A Large Population-Based and Propensity Score-Matched Study. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 37	5.3 5
419	GI Surgery Annual. <b>2019</b> ,	0
418	Advances in Translational Research and Clinical Care in Pancreatic Cancer: Where Are We Headed?. <b>2019</b> , 2019, 7690528	6
417	Serum carcinoembryonic antigen to predict recurrence in the follow-up of patients with colorectal cancer. <b>2019</b> , 34, 60-68	13
416	A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. <b>2019</b> , 9, 1280-1287	28



415 Molecular Diagnostics in Pancreatic Cancer. **2019**, 157-163

414 Roles of Methylated DNA Biomarkers in Patients with Colorectal Cancer. **2019**, 2019, 2673543 19

413 Analysis of bodily fluids using vibrational spectroscopy: a direct comparison of Raman scattering and infrared absorption techniques for the case of glucose in blood serum. **2019**, 144, 3334-3346 17

412 Proteomic and genomic profiling of pancreatic cancer. **2019**, 35, 333-343 35

411 Pancreatic and Ovarian Cancer Biomarkers. **2019**, 855-867

410 Trimethylamine-N-oxide as One Hypothetical Link for the Relationship between Intestinal Microbiota and Cancer - Where We Are and Where Shall We Go?. **2019**, 10, 5874-5882 32

409 Prognostic nomograms for predicting cause-specific survival and overall survival of stage I-III colon cancer patients: a large population-based study. **2019**, 19, 355 16

408 Circulating natural antibodies against 3'-sialyllactose complement the diagnostic performance of CA19-9 for the early detection of pancreatic ductal adenocarcinoma. **2020**, 27, 121-128 2

407 Plasma activity of Thioredoxin Reductase as a Novel Biomarker in Gastric Cancer. **2019**, 9, 19084 11

406 Elevated Pretreatment CEA and CA19-9 Levels are Related to Early Treatment Failure in Esophageal Adenocarcinoma. **2019**, 42, 345-350 7

405 Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions. **2019**, 26, S43-S52 21

404 Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence Generation.. **2019**, 3, 1-10 2

403 Development of a Correlative Strategy To Discover Colorectal Tumor Tissue Derived Metabolite Biomarkers in Plasma Using Untargeted Metabolomics. **2019**, 91, 2401-2408 17

402 Transitioning Discoveries from Cancer Genomics Research Laboratories into Pathology Practice. **2019**, 149-162

401 A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma. **2019**, 34, 330-345 11

400 Combination of D-dimer and carcinoembryonic antigen levels as a predictive and prognostic biomarker in advanced colorectal cancer patients. **2018**, 120, 8086 6

399 24 Rectal Adenocarcinoma. **2019**,

398 Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer. *Annals of Surgical Oncology*, **2019**, 26, 807-814 3.1 12

397	Long noncoding RNA ENST00000455974 plays an oncogenic role through up-regulating JAG2 in human DNA mismatch repair-proficient colon cancer. <b>2019</b> , 508, 339-347		9
396	Recomendaciones para la optimizaci3n del uso de marcadores tumorales de utilizaci3n frecuente. Recomendaci3n (2018). <b>2019</b> , 12, 38-52		0
395	Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer. <b>2019</b> , 28, 174-182		20
394	Circulating pancreatic cancer exosomal RNAs for detection of pancreatic cancer. <b>2019</b> , 13, 212-227		36
393	Tumor markers: myths and facts unfolded. <b>2019</b> , 44, 1575-1600		15
392	Intertumoral Heterogeneity of CD3 and CD8 T-Cell Densities in the Microenvironment of DNA Mismatch-Repair-Deficient Colon Cancers: Implications for Prognosis. <b>2019</b> , 25, 125-133		34
391	The clinicopathological variables to differentiate the nature of isolated pulmonary nodules in patients who received curative surgery for colorectal cancer. <b>2019</b> , 42, 425-432		3
390	Hypoxia-Induced TGFBI as a Serum Biomarker for Laboratory Diagnosis and Prognosis in Patients with Pancreatic Ductal Adenocarcinoma. <b>2020</b> , 51, 352-361		1
389	Interrelationship between oxidative stress, DNA damage and cancer risk in diabetes (Type 2) in Riyadh, KSA. <b>2020</b> , 27, 177-183		6
388	A comprehensive and comparative review of optimal cut-points selection methods for diseases with multiple ordinal stages. <b>2020</b> , 30, 46-68		6
387	Extracellular vesicles as biomarkers and therapeutic targets for cancer. <b>2020</b> , 318, C29-C39		47
386	Identification and Validation of Stage-Associated Serum Biomarkers in Colorectal Cancer Using MS-Based Procedures. <b>2020</b> , 14, e1900052		4
385	Circulating epigenetic biomarkers for detection of recurrent colorectal cancer. <b>2020</b> , 126, 1460-1469		18
384	Serum IGFBP-1 as a potential biomarker for diagnosis of early-stage upper gastrointestinal tumour. <b>2020</b> , 51, 102566		6
383	The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 2017-2024	3.1	5
382	Study on glycoprotein terahertz time-domain spectroscopy based on composite multiscale entropy feature extraction method. <b>2020</b> , 229, 117948		9
381	The role of exosomes in colorectal cancer disease progression and response to therapy. <b>2020</b> , 51, 84-91		10
380	Identification of a Collagen Marker in Urine Improves the Detection of Colorectal Liver Metastases. <b>2020</b> , 19, 153-160		5

379	Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. <b>2020</b> , 214, 362-369	14
378	Surgical treatment following neoadjuvant chemoradiotherapy in locally advanced rectal cancer. <b>2020</b> , 36, 152-159	8
377	Prognostic impact of preoperatively elevated and postoperatively normalized carcinoembryonic antigen levels following curative resection of stage I-III rectal cancer. <b>2020</b> , 9, 653-662	17
376	Colorectal Cancer. <b>2020</b> , 1219-1280.e15	3
375	Association of T Stage and Serum CEA Levels in Determining Survival of Rectal Cancer. <i>Frontiers in Medicine</i> , <b>2019</b> , 6, 270	4-9 3
374	Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, and YKL-40. <b>2020</b> , 49, 53-61	6
373	. <b>2020</b> ,	
372	High mobility group A protein-2 as a tumor cancer diagnostic and prognostic marker: a systematic review and meta-analysis. <b>2020</b> , 29, 565-581	0
371	Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2020</b> , 31, 1291-1305	165
370	Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma. <b>2021</b> , 75, 153-168	13
369	Establishment and validation of a novel nomogram incorporating clinicopathological parameters into the TNM staging system to predict prognosis for stage II colorectal cancer. <b>2020</b> , 20, 285	4
368	Immune-Directed Molecular Imaging Biomarkers. <b>2020</b> , 50, 584-603	2
367	Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. <b>2020</b> , 70, 375-403	72
366	Hist-Immune signature: a prognostic factor in colorectal cancer using immunohistochemical slide image analysis. <b>2020</b> , 9, 1841935	2
365	Identification of Patients with Pancreatic Cancer by Electron Paramagnetic Resonance Spectroscopy of Fatty Acid Binding to Human Serum Albumin. <b>2020</b> , 3, 1188-1198	2
364	Construction and Validation of a Protein Prognostic Model for Lung Squamous Cell Carcinoma. <b>2020</b> , 17, 2718-2727	2
363	Urinary charged metabolite profiling of colorectal cancer using capillary electrophoresis-mass spectrometry. <b>2020</b> , 10, 21057	7
362	Predictive Value of Carcinoembryonic Antigen in Symptomatic Patients without Colorectal Cancer: A Post-Hoc Analysis within the COLONPREDICT Cohort. <b>2020</b> , 10,	1

361	Why recurrence was initially suspected during colorectal cancer postoperative surveillance?: A retrospective analysis. <b>2020</b> , 99, e22803	3
360	Inflammation, Tumoral Markers and Interleukin-17, -10, and -6 Profiles in Pancreatic Adenocarcinoma and Chronic Pancreatitis. <b>2021</b> , 66, 3427-3438	1
359	Biodetection and sensing for cancer diagnostics. <b>2020</b> , 643-660	2
358	Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases. <b>2020</b> , 15, e0236569	7
357	Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mirna: a substudy of the TiMiSNAR Trial (NCT03962088). <b>2020</b> , 21, 678	0
356	Serum levels of carbohydrate antigen 19-9 do not systematically increase in case of liver cyst infection in patients with autosomal dominant polycystic kidney disease. <b>2020</b> , 13, 482-483	1
355	Synergistic Association of Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 on the Risk of Abnormal Glucose Regulation. <b>2020</b> , 13, 1933-1942	1
354	Prognostic value of lymphocyte to monocyte ratio in pancreatic cancer: a systematic review and meta-analysis including 3338 patients. <b>2020</b> , 18, 186	8
353	A Prognostic Nomogram Based on Immune Scores Predicts Postoperative Survival for Patients with Hepatocellular Carcinoma. <b>2020</b> , 2020, 1542394	2
352	The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. <b>2020</b> , 20, 662-680	288
351	Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer. <b>2020</b> , 59, 1416-1423	6
350	The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Rectal Cancer. <b>2020</b> , 63, 1191-1222	51
349	Lewis Antigen Phenotype and Survival of Patients With Pancreatic Cancer. <b>2020</b> , 49, 1348-1354	1
348	Limited usefulness of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for gastrointestinal and whole-body cancer screening. <b>2020</b> , 10, 18202	3
347	Predictive value of changes in the level of carbohydrate antigen 19-9 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. <b>2020</b> , 22, 2068-2077	3
346	Circulating Tumour DNAs and Non-Coding RNAs as Liquid Biopsies for the Management of Colorectal Cancer Patients. <b>2020</b> , 2, 212-235	5
345	Claudin-1 Is a Valuable Prognostic Biomarker in Colorectal Cancer: A Meta-Analysis. <b>2020</b> , 2020, 4258035	2
344	Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and functional imaging techniques. <b>2020</b> , 45, 4273-4289	2

343	Liquid Biopsy of Extracellular Vesicle-Derived miR-193a-5p in Colorectal Cancer and Discovery of Its Tumor-Suppressor Functions. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1372	5.3	5
342	Predictive and Prognostic Markers for Cancer Medicine. <b>2020</b> , 157-201		1
341	Study on the Diagnosis of Gastric Cancer by Magnetic Beads Extraction and Mass Spectrometry. <b>2020</b> , 2020, 2743060		1
340	Status Quo of Glycosylation in Cancer: What Is, What Is Not and What Is to Be. <b>2020</b> , 10, 8401		
339	Insights into Bioinformatic Applications for Glycosylation: Instigating an Awakening towards Applying Glycoinformatic Resources for Cancer Diagnosis and Therapy. <b>2020</b> , 21,		1
338	Postoperative serum carcinoembryonic antigen levels cannot predict survival in colorectal cancer patients with type II diabetes. <b>2020</b> , 83, 911-917		2
337	Proteomic Characterization of Colorectal Cancer Cells versus Normal-Derived Colon Mucosa Cells: Approaching Identification of Novel Diagnostic Protein Biomarkers in Colorectal Cancer. <b>2020</b> , 21,		10
336	Nomograms for predicting specific distant metastatic sites and overall survival of colorectal cancer patients: A large population-based real-world study. <b>2020</b> , 10, 169-181		15
335	Identification of a competing endogenous RNA network associated with prognosis of pancreatic adenocarcinoma. <b>2020</b> , 20, 231		13
334	Complementary Use of Carbohydrate Antigens Lewis a, Lewis b, and Sialyl-Lewis a (CA19.9 Epitope) in Gastrointestinal Cancers: Biological Rationale Towards A Personalized Clinical Application. <i>Cancers</i> , <b>2020</b> , 12,	6.6	6
333	gene polymorphisms and related indel as predictor biomarkers of treatment response for colorectal cancer - toward a personalized medicine. <b>2020</b> , 42, 1010428320925237		3
332	Prognostic value of postoperative serum carcinoembryonic antigen levels in colorectal cancer patients who smoke. <b>2020</b> , 15, e0233687		12
331	Clinical Significances of Positive Postoperative Serum CEA and Post-preoperative CEA Increment in Stage II and III Colorectal Cancer: A Multicenter Retrospective Study. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 671	5.3	7
330	Development and external validation of a predictive scoring system associated with metastasis of T1-2 colorectal tumors to lymph nodes. <b>2020</b> , 10, 275-287		10
329	Comprehensive Evaluation of Relapse Risk (CERR) Score for Colorectal Liver Metastases: Development and Validation. <b>2020</b> , 25, e1031-e1041		8
328	Clinical Significance of Preoperative Serum Carcinoembryonic Antigen Within the Normal Range in Colorectal Cancer Patients Undergoing Curative Resection. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 2774-2783	3.1	6
327	Texture Analysis: An Emerging Clinical Tool for Pancreatic Lesions. <b>2020</b> , 49, 301-312		6
326	Assessing the adherence to guidelines in Lynch syndrome patients: a pilot study. <b>2020</b> , 90, 1130-1135		

325	Serum AMDL DR-70 levels: a new concept in the diagnosis and follow-up of colorectal carcinoma. <b>2020</b> , 14, 621-628		4
324	Integrin $\beta$ promotes tumorigenicity and progressive capacity of colorectal cancer. <b>2020</b> , 16, 815-826		12
323	Monitoring Therapy Efficiency in Cancer through Extracellular Vesicles. <b>2020</b> , 9,		13
322	Predictive value of serum and tissue carcinoembryonic antigens for radiologic response and oncologic outcome of rectal cancer. <b>2020</b> , 216, 152834		6
321	Adrenal Tumors Found During Staging and Surveillance for Colorectal Cancer: Benign Incidentalomas or Metastatic Disease?. <i>World Journal of Surgery</i> , <b>2020</b> , 44, 2282-2287	3-3	1
320	Patient Selection for Adjuvant Chemotherapy in High-Risk Stage II Colon Cancer: A Systematic Review and Meta-Analysis. <b>2020</b> , 43, 279-287		11
319	Esophageal, gastric and colorectal cancers: Looking beyond classical serological biomarkers towards glycoproteomics-assisted precision oncology. <b>2020</b> , 10, 4903-4928		22
318	Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	19
317	Machine learning-based analysis of CT radiomics model for prediction of colorectal metachronous liver metastases. <b>2021</b> , 46, 249-256		20
316	Prognostic value of postoperative serum carcinoembryonic antigen levels in colorectal cancer patients with chronic kidney disease. <b>2021</b> , 221, 162-167		1
315	Surgical management of biliary malignancy. <b>2021</b> , 58, 100854		1
314	THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement. <b>2021</b> , 14, 223-232		5
313	Prognostic Value of Pretreatment Serum CA199 in Patients with Locally Advanced Rectal Cancer Treated with CRT Followed by TME with Normal Pretreatment Carcinoembryonic Antigen Levels. <b>2021</b> , 38, 24-29		2
312	A flux-adaptable pump-free microfluidics-based self-contained platform for multiplex cancer biomarker detection. <b>2021</b> , 21, 143-153		26
311	Serum tumor markers: A study on their rational use in various cancers. <b>2021</b> ,		
310	Identification of MicroRNA 15b-3p as a Diagnostic Marker for Early Stage of Colorectal Cancer Through Comprehensive RNA Analysis. <b>2021</b> , 67, 272-281		
309	Roles of miRNA dysregulation in the pathogenesis of multiple myeloma. <b>2021</b> , 28, 1256-1268		9
308	Overview of Pancreatic Masses and Cystic Lesions. <b>2021</b> , 1-17		

307	Single nanoparticle analysis for homogeneous immunoassay of CA19-9 for serological evaluation. <b>2021</b> , 36, 279-284		2
306	Development and Multiple Validation of the Protein Multi-marker Panel for Diagnosis of Pancreatic Cancer. <b>2021</b> , 27, 2236-2245		5
305	Differential diagnosis between pancreatic involvement in IgG4-related disease and pancreatic cancer. <b>2021</b> , 44, 144-155		2
304	High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9. <b>2021</b> , 27, 2523-2532		3
303	The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative. <b>2021</b> , 25, 2908-2919		1
302	Serum Levels of BDNF in Patients with Adenoma and Colorectal Cancer. <b>2021</b> , 2021, 8867368		1
301	Differential diagnosis between pancreatic involvement in IgG4-related disease and pancreatic cancer. <b>2021</b> , 44, 144-155		
300	Stratification of Chemotherapy-Treated Stage III Colorectal Cancer Patients Using Multiplexed Imaging and Single Cell Analysis of T Cell Populations.		
299	Can normalized carcinoembryonic antigen following neoadjuvant chemoradiation predict tumour recurrence after curative resection for locally advanced rectal cancer?. <b>2021</b> , 23, 1346-1356		1
298	Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer. <b>2021</b> , 9,		13
297	Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer. <b>2021</b> , 62, 1384-1390		0
296	A two-tiered targeted proteomics approach to identify pre-diagnostic biomarkers of colorectal cancer risk. <b>2021</b> , 11, 5151		4
295	Aptamer-Based Detection of Circulating Targets for Precision Medicine. <i>Chemical Reviews</i> , <b>2021</b> , 121, 12035-12105	68.1	61
294	Tumour markers with clinically controlled cut-offs for suspected cancer. <b>2021</b> , 51, e13523		1
293	Combining the Fecal Immunochemical Test with a Logistic Regression Model for Screening Colorectal Neoplasia. <b>2021</b> , 12, 635481		1
292	Nanotechnology and pancreatic cancer management: State of the art and further perspectives. <b>2021</b> , 13, 231-237		7
291	Carbohydrate Based Therapeutics.		
290	A Novel Prognostic Model and Practical Nomogram for Predicting the Outcomes of Colorectal Cancer: Based on Tumor Biomarkers and Log Odds of Positive Lymph Node Scheme. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 661040	5.3	5

289	Loss of enteric neuronal NdrG4 promotes colorectal cancer via increased release of Nid1 and Fbln2. <b>2021</b> , 22, e51913	6
288	Liver metastases. <b>2021</b> , 7, 27	24
287	Predictive models for colorectal cancer recurrence using multi-modal healthcare data. <b>2021</b> ,	
286	Profiling Colorectal Cancer in the Landscape Personalized Testing-Advantages of Liquid Biopsy. <b>2021</b> , 22,	2
285	Primary tumor resection improves prognosis of unresectable carcinomas of the transverse colon including flexures with liver metastasis: a preliminary population-based analysis. <b>2021</b> , 21, 503	
284	Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction. <b>2021</b> , 13, 111	9
283	Prognostic Impact of Carcinoembryonic Antigen Levels in Rectal Cancer Patients Who Had Received Neoadjuvant Chemoradiotherapy. <b>2021</b> , 37, 179-185	1
282	An integrated magneto-electrochemical device for the rapid profiling of tumour extracellular vesicles from blood plasma. <b>2021</b> , 5, 678-689	19
281	Identification of Fucosylated SERPINA1 as a Novel Plasma Marker for Pancreatic Cancer Using Lectin Affinity Capture Coupled with iTRAQ-Based Quantitative Glycoproteomics. <b>2021</b> , 22,	4
280	Association of perioperative serum carcinoembryonic antigen level and recurrence in low-risk stage IIA colon cancer. <b>2021</b> , 16, e0252566	1
279	The Effectiveness of Glutathione Redox Status as a Possible Tumor Marker in Colorectal Cancer. <b>2021</b> , 22,	2
278	High PHD Finger Protein 19 (PHF19) expression predicts poor prognosis in colorectal cancer: a retrospective study. <b>2021</b> , 9, e11551	3
277	The Role of Sex-specific Long Non-coding RNAs in Cancer Prevention and Therapy. <b>2021</b> , 26, 98-109	2
276	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. <b>2021</b> , 125, 839-845	2
275	Serum macrophage inhibitory cytokine-1 serves as a novel diagnostic biomarker of early-stage colorectal cancer. <b>2021</b> , 26, 598-605	0
274	Beyond Colonoscopy: Exploring New Cell Surface Biomarkers for Detection of Early, Heterogenous Colorectal Lesions. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 657701	53 1
273	Current Applications and Discoveries Related to the Membrane Components of Circulating Tumor Cells and Extracellular Vesicles. <b>2021</b> , 10,	2
272	Comparison of guidelines on rectal cancer: exception proves the rule?. <b>2021</b> , 9, 290-298	1



271	Constructing Tumor Immune Microenvironment and Identifying the Immune-Related Prognostic Signatures in Colorectal Cancer Using Multi-omics Data.		
270	Multiparameter MRI-based radiomics for preoperative prediction of extramural venous invasion in rectal cancer. <b>2021</b> , 1		1
269	Gene Expression Profiling for Differential Diagnosis of Liver Metastases: A Multicenter, Retrospective Cohort Study. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 725988	5.3	0
268	Biomarkers associated with different types of cancer as a potential candidate for early diagnosis of oncological disorders. <b>2022</b> , 47-57		3
267	The mtDNA Microsatellite Instability Indicated the Prognosis of Chinese Patients with Non-Hodgkin's Lymphoma. <b>2021</b> , 23, 141-148		
266	Biomarkers as Putative Therapeutic Targets in Colorectal Cancer. <b>2021</b> , 123-177		
265	Platelets induce free and phospholipid-esterified 12-hydroxyeicosatetraenoic acid generation in colon cancer cells by delivering 12-lipoxygenase. <b>2021</b> , 62, 100109		3
264	Postmenopausal Ovarian Cyst. <b>2021</b> , 207-222		
263	Overexpression of GDP dissociation inhibitor 1 gene associates with the invasiveness and poor outcomes of colorectal cancer. <b>2021</b> , 12, 5595-5606		1
262	Diagnostic and Therapeutic Response Markers. <b>2010</b> , 675-701		7
261	Colon and Rectum. <b>2010</b> , 143-164		35
260	Colon and Rectum. <b>2010</b> , 173-206		5
259	Targeted Clinical Trials. <b>2012</b> , 157-177		4
258	Data Mining for Cancer Biomarkers with Raman Spectroscopy. <b>2012</b> , 143-168		6
257	Metastatic Ovarian Tumors (Clinical Setting and US). <b>2013</b> , 335-364		3
256	Metabolic Biomarkers of Pancreatic Cancer. <b>2020</b> , 83-96		1
255	Colon and Rectum. <b>2017</b> , 251-274		35
254	Encyclopedia of Cancer. <b>2011</b> , 3390-3394		1

253	Cancer Biomarkers (An Overview). <b>2010</b> , 21-40	6
252	Molecular Prognostic Markers in Colon Cancer. <b>2010</b> , 321-341	1
251	Signal Transduction in Tumor-Endothelial Cell Communication. <b>2011</b> , 187-212	1
250	Biomarker Discovery in Biological Fluids. <b>2011</b> , 291-326	4
249	CA 19-9 as a Serum Biomarker in Cancer. <b>2015</b> , 179-201	2
248	Colorectal Cancer Circulating Biomarkers. <b>2015</b> , 573-599	2
247	Colorectal Cancer. <b>2009</b> , 879-897	2
246	Biomarkers for Cancer Diagnostics. <b>2008</b> , 277-282	1
245	Surveillance and Follow-up. <b>2011</b> , 201-217	1
244	Colorectal Cancer. <b>2014</b> , 1278-1335.e14	1
243	Artificial intelligence (AI) and big data in cancer and precision oncology. <b>2020</b> , 18, 2300-2311	50
242	CA19-9 for detecting recurrence of pancreatic cancer. <b>2020</b> , 10, 1332	38
241	Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer. <b>2020</b> , 8,	22
240	Novel biomarkers and endoscopic techniques for diagnosing pancreaticobiliary malignancy. <b>2017</b> , 6, 1643	5
239	Colorectal Cancer Biomarkers - A New Trend in Early Diagnosis. <b>2018</b> , 44, 140-146	5
238	Clinical significance of exosomes as potential biomarkers in cancer. <i>World Journal of Clinical Cases</i> , <b>2019</b> , 7, 171-190	1.6 39
237	Circulating exosomal microRNAs as biomarkers of colon cancer. <b>2014</b> , 9, e92921	547
236	Postoperative serum levels of sCD26 for surveillance in colorectal cancer patients. <b>2014</b> , 9, e107470	13

235	Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality. <b>2016</b> , 11, e0165615	23
234	Psychological effects of the intensified follow-up of the CEAwatch trial after treatment for colorectal cancer. <b>2017</b> , 12, e0184740	3
233	[History of tumor markers for cancers of the digestive system]. <b>2013</b> , 154, 810-9	1
232	The CEA-/lo colorectal cancer cell population harbors cancer stem cells and metastatic cells. <b>2016</b> , 7, 80700-80715	19
231	A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer. <b>2017</b> , 8, 29925-29934	7
230	Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer. <b>2017</b> , 8, 60149-60158	87
229	Quantitative mass spectrometry analysis reveals a panel of nine proteins as diagnostic markers for colon adenocarcinomas. <b>2018</b> , 9, 13530-13544	12
228	Increased serum levels of betatrophin in pancreatic cancer-associated diabetes. <b>2016</b> , 7, 42330-42339	5
227	THE Role of Preoperative carcinoembryonic antigen in recurrence of resectable colorectal carcinoma. <b>2020</b> , 59, 216-222	2
226	TM9SF4 expression in tumor tissues: a novel diagnostic biomarker for gastrointestinal tumors.. <b>2020</b> , 9, 6652-6659	1
225	Role of Cellular Biomolecules in Screening, Diagnosis and Treatment of Colorectal Cancer. <b>2019</b> , 20, 880-888	5
224	The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. <b>2013</b> , 13, 340-51	188
223	MicroRNAs in Colon and Rectal Cancer - Novel Biomarkers from Diagnosis to Therapy. <b>2020</b> , 20, 1211-1226	4
222	Stage Association of Preoperative Serum Carcinoembryonic Antigen with Gastric Adenocarcinoma in Iranian Patients. <b>2017</b> , 18, 2669-2672	2
221	Circulating MicroRNA-21 Expression as a Novel Serum Biomarker for Oral Sub-Mucous Fibrosis and Oral Squamous Cell Carcinoma. <b>2018</b> , 19, 1053-1057	15
220	Serum level of long noncoding RNA B3GALT5-AS1 as a diagnostic biomarker of colorectal cancer. <b>2020</b> , 16, 827-835	7
219	What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial. <b>2017</b> , 21, 1-60	14
218	Diagnostic Accuracy of Elevated Serum Carcinoembryonic Antigen for Recurrence in Postoperative Stage II Colorectal Cancer Patients: Comparison With Stage III. <b>2013</b> , 29, 155-9	8

217	Pretreatment Serum CEA as a Prognostic Factor for Rectal Cancer Treated with Preoperative Chemoradiotherapy. <b>2010</b> , 26, 39	2
216	Clinical significance of serial serum carcinoembryonic antigen values for treating rectal cancer with preoperative chemoradiotherapy. <b>2012</b> , 28, 205-12	6
215	Circulating microRNAs: novel biomarkers for esophageal cancer. <b>2010</b> , 16, 2348-54	42
214	Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resection. <b>2012</b> , 18, 2121-6	61
213	Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein. <b>2012</b> , 18, 4150-5	34
212	Pancreatic ductal adenocarcinoma screening: new perspectives. <b>2012</b> , 18, 4973-7	5
211	Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer. <b>2013</b> , 19, 4651-70	45
210	Advances in radiotherapy and targeted therapies for rectal cancer. <b>2014</b> , 20, 1-5	18
209	Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9. <b>2015</b> , 21, 6604-12	17
208	Molecular detection of pancreatic neoplasia: Current status and future promise. <b>2015</b> , 21, 11387-95	20
207	Role of LAPCD4 T cells in the tumor microenvironment of colorectal cancer. <b>2017</b> , 23, 455-463	12
206	Prognostic value of preoperative carcinoembryonic antigen/tumor size in rectal cancer. <b>2019</b> , 25, 4945-4958	14
205	Prognostic value of changes in serum carcinoembryonic antigen levels for preoperative chemoradiotherapy response in locally advanced rectal cancer. <b>2020</b> , 26, 7022-7035	5
204	Delayed radiation-induced inflammation accompanying a marked carbohydrate antigen 19-9 elevation in a patient with resected pancreatic cancer. <b>2016</b> , 34, 156-9	2
203	Imaging performance and preoperative differential diagnosis of multiple myopericytoma in the liver: A case report. <b>2020</b> , 13, 66	1
202	Abnormal expression of ABCD3 is an independent prognostic factor for colorectal cancer. <b>2020</b> , 19, 3567-3577	5
201	Clinical Implication of Tumor Markers. <b>2012</b> , 83, 197	1
200	Detection of circulating tumor cells in cancers of biliary origin. <b>2012</b> , 3, 97-104	28

199	Ca19-9 and pancreatic cancer: Is it really that good?. <b>2012</b> , 3, 88-9	14
198	Glypican-1 in exosomes as biomarker for early detection of pancreatic cancer. <b>2016</b> , 4, 64	38
197	Usefulness of Carbohydrate Antigen 19-9 Test in Healthy People and Necessity of Medical Follow-up in Individuals with Elevated Carbohydrate Antigen 19-9 Level. <b>2019</b> , 40, 314-322	9
196	Tumor markers in clinical practice: General principles and guidelines. <b>2009</b> , 30, 1-8	85
195	Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy. <b>2013</b> , 45, 55-62	13
194	Precision medicine for gastrointestinal cancer: Recent progress and future perspective. <b>2020</b> , 12, 1-20	13
193	Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening. <b>2012</b> , 4, 145-51	16
192	The molecular targets for the diagnosis and treatment of pancreatic cancer. <b>2010</b> , 4, 433-49	17
191	Novel biomarkers for the diagnosis and prognosis of colorectal cancer. <b>2020</b> , 18, 168-183	33
190	Requests for tumor marker tests in Turkey without indications and frequency of elevation in benign conditions. <b>2012</b> , 13, 6485-9	2
189	Serum carbohydrate antigen 19-9 as an indicator of liver metastasis in colorectal carcinoma cases. <b>2013</b> , 14, 909-13	14
188	Carbohydrate antigen 19-9 levels associated with pathological responses to preoperative chemoradiotherapy in rectal cancer. <b>2014</b> , 15, 5383-7	5
187	Promoter Methylation Status of Two Novel Human Genes, UBE2Q1 and UBE2Q2, in Colorectal Cancer: a New Finding in Iranian Patients. <b>2015</b> , 16, 8247-52	11
186	Predictive value of CONUT score combined with serum CA199 levels in postoperative survival of patients with pancreatic ductal adenocarcinoma: a retrospective study. <b>2020</b> , 8, e8811	6
185	Capillary Electrophoresis-Based N-Glycosylation Analysis in the Biomedical and Biopharmaceutical Fields. <b>2021</b> , 1336, 129-137	
184	Fecal CEA Has an Advantage in the Diagnosis of Colorectal Cancer at Early Stage. <b>2021</b> , 28, 10732748211048292	
183	Clinical Significance of and Predictive Risk Factors for the Postoperative Elevation of Carcinoembryonic Antigen in Patients With Non-Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 741309	5.3 0
182	Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development. <b>2021</b> , 340, 1-34	1

- 181 Prognostic Value of Preoperative Serum Levels of CEA and CA19-9 in Patients with Colorectal Cancer. **2007**, 23, 338
- 180 [Significance of biomarkers and surrogate endpoints in preclinical and clinical trials]. **2007**, 64, 561-7
- 179 Circulating Tumor Markers. **2008**, 107-116
- 178 Genomic Instability in Colorectal Cancer; from Bench to Bed. **2009**, 25, 129
- 177 Rare Tumors of Childhood. **2009**, 989-1013
- 176 Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab. **2009**, 2, 161-70 2
- 175 Cancer of the Colon. **2010**, 842-850
- 174 Principles and Applications of Proteomics in Pancreatic Cancer. **2010**, 509-533
- 173 Cancer of the Rectum. **2010**, 851-869
- 172 Practical Gastrointestinal Oncology Correlative Science. **2011**, 43-66
- 171 Laboratory Diagnosis of Gastrointestinal and Pancreatic Disorders. **2011**, 312-328 1
- 170 Diagnostic and Prognostic Cancer Biomarkers: From Traditional to Systems Approaches. **2011**, 329-366
- 169 Chemotherapy and Biomarkers. **2012**, 187-200
- 168 Differing Serum Cea in Primary and Recurrent Rectal Cancer - A Reflection of Histology?. **2012**, 3, 59-63 4
- 167 Tumor Markers. **2012**, 617-667 1
- 166 Pathological Complete Remission in Young Colon Cancer Patient with a Large Liver Metastasis after FOLFOX-4/Bevacizumab Treatment [A Case Report. **2012**, 03, 307-310 1
- 165 Colorectal Cancer. **2012**, 245-272
- 164 Prognostic Markers in Colon Cancer. **2013**, 131-162

163 Serological Markers of Digestive Tract Cancers. **2013**, 249-270

162 Cancers of the Rectum and Anal Canal. **2013**, 141-171

161 Pancreatic Cancer and Gastroenterology: A Review. **2013**, 6, 81-84

2

160 CEA. **2013**, 1-13

159 Encyclopedia of Cancer. **2014**, 1-7

158 Encyclopedia of Cancer. **2014**, 4194-4199

157 Transitioning Discoveries from Cancer Genomics Research Laboratories into Pathology Practice. **2015**, 159-175

156 Fluorophore-Conjugated Chimeric Anti-CEA Antibodies for Fluorescence-Guided Surgery of Gastrointestinal (GI) Tumors. **2015**, 209-222

155 Diagnosing Biliary Strictures and Indeterminate Biliary Strictures. **2015**, 111-130

154 Peutz-Jeghers Syndrome. **2016**, 117-164

153 Glycans in Medicinal Chemistry. **2016**,

152 Relation between the Half-life of Serum CEA during First-line Chemotherapy and the Overall Survival in Patients with Metastatic Colorectal Carcinoma. **2016**, 77, 2148-2152

151 Prognostic Factors for Recurrence after Tegafur-uracil Plus Leucovorin Adjuvant Chemotherapy in Patients with Colorectal Cancer. **2016**, 28, 19-30

150 Gastrointestinal Malignancy: Genetic Implications to Clinical Applications. **2016**, 168, 393-479

149 Diagnosis and Screening for Pancreatic Malignancy. **2017**, 93-99

148 Development of Novel Diagnostic Pancreatic Tumor Biomarkers 2nd ed. **2017**, 1-32

147 Clinical Predictors of Cetuximab for First-Line Therapy of Metastatic Colorectal Cancer: A Single Institutional Retrospective Study. **2017**, 08, 827-837

146 Secondary Screening for Inherited Pancreatic Ductal Adenocarcinoma. **2017**, 1-34

- 145 Current and Emerging Therapies in Pancreatic Cancer. **2018**, 119-134
- 144 Early Serum Carcinoembryonic Antigen Reduction Predicts Tumor Shrinkage and Overall Survival in Colorectal Cancer Patients with Distant Metastasis, after Primary Surgery Followed by Mfolfox6 Plus Bevacizumab Treatment. **2018**, 08, 147-153
- 143 Development of a prognostic nomogram for metastatic colorectal cancer patients: The study protocol of a multicenter, retrospective, observational, cohort study. **2018**, 26, 116-119
- 142 Pancreatic Cancer. **2019**, 421-470
- 141 Increased cancer-specific mortality of very small size in carcinoembryonic antigen-elevated rectal cancer. **2019**, 7, 447 1
- 140 Role of circulating miRNA-17-3P as a potential diagnostic biomarker for sporadic colon cancer in Egyptian cohort. **2020**, 10,
- 139 Phenome-wide association study of a comprehensive health check-up database in a Korea population: Clinical application & trans-ethnic comparison.
- 138 An Overview on Cancer Diagnosis based on Antibody-Based Immune Techniques. **2020**, 3, 100-110
- 137 Using the polymeric circulating tumor cell chip to capture circulating tumor cells in blood samples of patients with colorectal cancer. **2020**, 19, 2286-2294 3
- 136 Challenges and Opportunities for Early Pancreatic Cancer Detection: Role for Protein Biomarkers. **2020**, 73-82
- 135 Gastrointestinal Endoscopy for Patients with High Levels of Serum CEA and CA19-9. **2020**, 32, 115-123 1
- 134 Proteostasis Dysregulation in Pancreatic Cancer. **2020**, 1233, 101-115 3
- 133 Proteomics-Based Identification of Candidate Exosomal Glycoprotein Biomarkers and Their Value for Diagnosing Colorectal Cancer. *Frontiers in Oncology*, **2021**, 11, 725211 5-3 3
- 132 Stratification of chemotherapy-treated stage III colorectal cancer patients using multiplexed imaging and single-cell analysis of T-cell populations. **2021**, 2
- 131 Special Diagnostics. **2008**, 39-64
- 130 Surgical Treatment Approaches to the Colorectal Cancers in the Light of the Current Guidelines. **2021**, 269-284
- 129 Follow-Up of Patients with Surgical Colorectal Cancer Resection. **2021**, 419-433
- 128 Role of Tumour Markers CEA and CA19-9 in Colorectal Cancer. **2020**, 9, 3483-3488



127	Options of Colorectal Cancer Screening: An Overview. <b>2021</b> , 29-40	
126	Clinical Value of CXCL5 for Determining of Colorectal Cancer. <b>2018</b> , 19, 2481-2484	11
125	Diagnostic and prognostic biomarkers in pancreatic carcinoma. <b>2009</b> , 2, 1-10	15
124	Predictive and prognostic markers in colorectal cancer. <b>2007</b> , 1, 237-46	9
123	Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. <b>2007</b> , 1, 146-54	26
122	Accomplishments in 2007 in the adjuvant treatment of colorectal cancer. <b>2008</b> , 2, S2-6	1
121	Accomplishments in 2008 in the adjuvant treatment of colon cancer. <b>2009</b> , 3, S2-7	1
120	Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy. <b>2009</b> , 3, 191-6	12
119	Risk factors for pancreatic adenocarcinoma and prospects for screening. <b>2010</b> , 6, 246-54	13
118	Assessing outcomes following surgery for colorectal cancer using quality of care indicators. <b>2010</b> , 53, 232-40	21
117	Prognostic values of chromosome 18q microsatellite alterations in stage II colonic carcinoma. <b>2010</b> , 16, 6026-34	7
116	CA 19-9 and pancreatic cancer. <b>2013</b> , 11, 53-5	24
115	Translating clinical research of Molecular Biology into a personalized, multidisciplinary approach of colorectal cancer patients. <b>2014</b> , 7, 17-26	3
114	New intracellular and molecular aspects in pathophysiology of colorectal cancer. <b>2011</b> , 4, 43-52	2
113	Serum CA19-9 in patients with solid pancreatic mass. <b>2013</b> , 6, 32-5	1
112	Rectal cancer: a review. <b>2015</b> , 29, 171	14
111	Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients. <b>2015</b> , 8, 14853-63	18
110	Identification and verification of PRDX1 as an inflammation marker for colorectal cancer progression. <b>2016</b> , 8, 842-59	10

109	Hydroxylated collagen peptide in urine as biomarker for detecting colorectal liver metastases. <b>2016</b> , 6, 321-30	8
108	Carcinoembryonic Antigen Expression and Resistance to Radiation and 5-Fluorouracil-Induced Apoptosis and Autophagy. <b>2016</b> , 5, 80-9	9
107	Methylation of serum gene is an independent prognostic marker in colorectal cancer. <b>2016</b> , 6, 2098-2108	19
106	Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes. <b>2018</b> , 8, 332-353	23
105	Expression of NIBP and its clinical significance in human early colorectal cancer. <b>2017</b> , 10, 8633-8639	
104	Meprin E combined with CEA and CA19-9 improves prognostic prediction for surgically treated colorectal cancer patients. <b>2017</b> , 10, 10441-10450	1
103	Decreased vitamin D receptor protein expression is associated with progression and poor prognosis of colorectal cancer patients. <b>2020</b> , 13, 746-755	2
102	Part Three of Three-Part Series: Colorectal Surgery Review for Primary Care Providers. <b>2020</b> , 117, 383-387	
101	Is There any Survival Benefit of Maintenance Chemotherapy Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer Patients with Post-Surgery Elevated CA 19-9?. <b>2020</b> , 21, 74-80	
100	Circulating miRNA expression over the course of colorectal cancer treatment. <b>2022</b> , 23, 18	0
99	The correlation of immunoscore and frailty in colorectal cancer. <b>2021</b> , 1	0
98	Liquid Biopsy-Based Colorectal Cancer Screening via Surface Markers of Circulating Tumor Cells. <b>2021</b> , 11,	0
97	Trajectories of Perioperative Serum Tumor Markers and Colorectal Cancer Outcomes: A Retrospective, Multicenter Longitudinal Cohort Study. <b>2021</b> , 74, 103706	0
96	Robust deep learning model for prognostic stratification of pancreatic ductal adenocarcinoma patients.. <b>2021</b> , 24, 103415	0
95	Clinical significance of controlling nutritional status score (CONUT) in evaluating outcome of postoperative patients with gastric cancer.. <b>2022</b> , 12, 93	1
94	Current advances in prognostic and diagnostic biomarkers for solid cancers: Detection techniques and future challenges. <b>2021</b> , 146, 112488	2
93	Validation of Serum Biomarkers That Complement CA19-9 in Detecting Early Pancreatic Cancer Using Electrochemiluminescent-Based Multiplex Immunoassays.. <b>2021</b> , 9,	2
92	Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications.. <b>2022</b> ,	0

91	Adoptive T-Cell Therapy in Advanced Colorectal Cancer: A Systematic Review.. <b>2022</b> , 27, 210-219		0
90	Dynamic monitoring of carcinoembryonic antigen, CA19-9 and inflammation-based indices in patients with advanced colorectal cancer undergoing chemotherapy.. <i>World Journal of Clinical Cases</i> , <b>2022</b> , 10, 899-918	1.6	0
89	Validation of Urinary Charged Metabolite Profiles in Colorectal Cancer Using Capillary Electrophoresis-Mass Spectrometry.. <b>2022</b> , 12,		2
88	C-Reactive Protein as Predictive Biomarker for Response to Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Retrospective Study.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
87	Is CA19-9 effective in predicting chemotherapeutic response in patients with synchronous liver metastases with colorectal cancer?. <b>2022</b> , 28, 500-501		0
86	Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes.. <b>2022</b> , 75, 103802		2
85	Tumour- associated autoantibodies as prognostic cancer biomarkers- a review.. <b>2022</b> , 21, 103041		3
84	Quels marqueurs circulants pour quels cancers?. <b>2007</b> , 23, 23		
83	Oxidative Stress and Gender Disparity in Cancer.. <b>2022</b> , 1-39		0
82	Classification of early-stage colon cancer with Immunoscore: clinical evidence and case studies.. <b>2021</b> ,		1
81	Critical review and meta-analysis of biological variation estimates for tumor markers.. <b>2022</b> ,		6
80	Contribution of Epithelial and Gut Microbiome Inflammatory Biomarkers to the Improvement of Colorectal Cancer Patients' Stratification.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 811486	5.3	0
79	Leveraging deep phenotyping from health check-up cohort with 10,000 Korean individuals for phenome-wide association study of 136 traits.. <b>2022</b> , 12, 1930		0
78	Development of a dynamic network biomarkers method and its application for detecting the tipping point of prior disease development.. <b>2022</b> , 20, 1189-1197		0
77	Recent advances in the selection of cancer-specific aptamers for the development of biosensors.. <b>2022</b> ,		1
76	Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease.. <b>2022</b> , 14, 28		0
75	Detection of Early-Stage Pancreatic Ductal Adenocarcinoma from blood samples: Results of a multiplex biomarker signature validation study.. <b>2022</b> , 13,		3
74	Prevalence of elevated Anti-p53 in Chinese patients with upper gastrointestinal or colorectal cancer.. <b>2022</b> , 3936155221078602		

73	Advances in High Throughput Proteomics Profiling in Establishing Potential Biomarkers for Gastrointestinal Cancer.. <b>2022</b> , 11,		1
72	A CT-Based Radiomics Nomogram in Predicting the Postoperative Prognosis of Colorectal Cancer: A Two-center Study.. <b>2022</b> ,		1
71	Colorectal Cancer: Preoperative Evaluation and Staging.. <b>2022</b> , 31, 127-141		3
70	Serum carcinoembryonic antigen and carbohydrate antigen 19-9 as preoperative diagnostic biomarkers of extrahepatic bile duct cancer.. <b>2021</b> , 5,		0
69	Tumor irradiation may facilitate the detection of tumor-specific mutations in plasma.. <b>2021</b> , 12, 1215-1226		
68	Application of droplet digital polymerase chain reaction of plasma methylated septin 9 on detection and early monitoring of colorectal cancer. <b>2021</b> , 11, 23446		0
67	Circadian and chemotherapy-related changes in urinary modified nucleosides excretion in patients with metastatic colorectal cancer.. <b>2021</b> , 11, 24015		
66	Đh gi ket qua som t̄eu tri ung th̄i tr̄ng bang phau thuat noi soi. <b>2021</b> ,		0
65	Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B.. <b>2021</b> , 16, e0262198		0
64	Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). <b>2021</b> , 59,		2
63	Predictive Values of the Selected Inflammatory Indexes in Colon Cancer.. <b>2022</b> , 29, 10732748221091333		1
62	Serum Proteins, HMMR, NXPH4, PITX1 and THBS4; A Panel of Biomarkers for Early Diagnosis of Hepatocellular Carcinoma.. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11,	5.1	3
61	Prognostic factor of serum carcinoembryonic antigen in colorectal cancer patients: a follow up study. <i>Al Mustansiriyah Journal of Pharmaceutical Sciences</i> , <b>2022</b> , 21, 1-6	1	
60	Data_Sheet_1.PDF. <b>2020</b> ,		
59	Data_Sheet_2.PDF. <b>2020</b> ,		
58	Cancer-Associated and Related Glycosphingolipid Antigens. 227-262		1
57	An Assessment of Physicians' Recommendations for Colorectal Cancer Screening and International Guidelines Awareness and Adherence: Results From a Thai National Survey.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 847361	4.9	
56	Role of artificial intelligence in early detection and screening for pancreatic adenocarcinoma. <i>Artificial Intelligence in Medical Imaging</i> , <b>2022</b> , 3, 21-32	0.6	

55	Preoperative Serum Carbohydrate Antigen 19-9 Levels Cannot Predict the Surgical Resectability of Pancreatic Cancer: A Meta-Analysis. <i>Pathology and Oncology Research</i> , 28,	2.6	
54	Identification and Validation of Apparent Imbalanced Epi-lncRNAs Prognostic Model Based on Multi-Omics Data in Pancreatic Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9,	5.6	1
53	Potentials of long non-coding RNAs as biomarkers of colorectal cancer.. <i>Clinical and Translational Oncology</i> , 2022,	3.6	0
52	Circulating miR-627-5p and miR-199a-5p are promising diagnostic biomarkers of colorectal neoplasia. <i>World Journal of Clinical Cases</i> , 2022, 10, 5165-5184	1.6	1
51	Combined Efficacy of CXCL5, STC2, and CHI3L1 in the Diagnosis of Colorectal Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-10	4.5	0
50	Leptomeningeal disease in BRIP1-mutated pancreatic adenocarcinoma. <i>BMJ Case Reports</i> , 2022, 15, e249837	0.7	0
49	ASO Author Reflections: CEA Uptrend is a Useful Biomarker to Predict Post-Hepatectomy Survival Outcomes in Patients with Colorectal Liver Metastasis. <i>Annals of Surgical Oncology</i> ,	3.1	
48	Impact of Preoperative CEA Uptrend on Survival Outcomes in Patients with Colorectal Liver Metastasis After Hepatectomy. <i>Annals of Surgical Oncology</i> ,	3.1	0
47	Elevated Carcinoembryonic Antigen at the Time of Recurrence as a Poor Prognostic Factor in Colorectal Cancer: A Propensity Score Matching Analysis. <i>Frontiers in Oncology</i> , 12,	5.3	
46	Application of informatics in cancer research and clinical practice: Opportunities and challenges.		
45	Plasma thioredoxin reductase: a potential diagnostic biomarker for gastric cancer. <i>Carcinogenesis</i> ,	4.6	
44	Gastric Adenocarcinoma of the Remnant Stomach Presenting With a Cystic Intra-abdominal Mass 11 Years After Roux-en-Y Gastric Bypass. <i>ACG Case Reports Journal</i> , 2022, 9, e00810	0.6	0
43	Salivary metabolomics with machine learning for colorectal cancer detection. <i>Cancer Science</i> ,	6.9	1
42	High-Throughput Glycomic Methods. <i>Chemical Reviews</i> ,	68.1	1
41	Type IV Collagen in Human Colorectal Liver Metastases: Cellular Origin and a Circulating Biomarker. <i>Cancers</i> , 2022, 14, 3396	6.6	0
40	Clinical significance of tumor markers in patients with type 2 diabetes: a retrospective observational study. <i>Diabetology International</i> ,	2.3	
39	Independent validation and assay standardization of improved metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. <i>Gastroenterology</i> , 2022,	13.3	2
38	Prognostic Value of Carcinoembryonic Antigen Changes Before and After Operation for Esophageal Squamous Cell Carcinoma. <i>World Journal of Surgery</i> ,	3.3	0

- 37 Malignancies in HIV. **2021**, 313-354
- 36 Diagnostic and prognostic biomarkers in colorectal cancer and the potential role of exosomes in drug delivery. **2022**, 110413 0
- 35 Circulating Cells with Macrophage-like Characteristics in Cancer: The Importance of Circulating Neoplastic-Immune Hybrid Cells in Cancer. **2022**, 14, 3871 2
- 34 Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems. **2022**, 20, 2
- 33 Current Screening Strategies for Pancreatic Cancer. **2022**, 10, 2056 0
- 32 Reclassifying TNM stage I/II colorectal cancer into two subgroups with different overall survival, tumor microenvironment, and response to immune checkpoint blockade treatment. 13, 0
- 31 Preoperative Absolute Lymphocyte Count to Carcinoembryonic Antigen Ratio Is a Superior Predictor of Survival in Stage I to III Colorectal Cancer. **2022**, 16, 117955492211262 0
- 30 Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study. **2022**, 22, 1
- 29 Preoperative carcinoembryonic antigen to body mass index ratio contributes to prognosis prediction in colorectal cancer. **2022**, 24, 0
- 28 Preoperative low absolute lymphocyte count to fibrinogen ratio correlated with poor survival in nonmetastatic colorectal cancer. **2022**, 20, 0
- 27 Biomarkers in Liquid Biopsies for Prediction of Early Liver Metastases in Pancreatic Cancer. **2022**, 14, 4605 0
- 26 Current trends in the diagnosis of pancreatic cancer. **2022**, 68, 363-370 0
- 25 Building a prognostic model based on Cytokine-related genes and exploration of colon cancer prognostic indicators. 0
- 24 Prime Editing: An Emerging Tool in Cancer Treatment. 0
- 23 Development and validation of a nomogram for patients with stage II/III gastric adenocarcinoma after radical surgery. 9, 0
- 22 Molecular Diagnostics in Cancer. 1-14 0
- 21 Carbohydrate antigen 19-9 plus carcinoembryonic antigen for prognosis in colorectal cancer: An observational study. 0
- 20 The role of circadian gene timeless in gastrointestinal cancers. **2023**, 30, 101722 0

- 19 Colorectal Cancer Biosensor Using Vertically-Oriented Silicon Nanowires. **2022**, ○
- 18 Combined plasma C-reactive protein, interleukin 6 and YKL -40 for detection of cancer and prognosis in patients with serious nonspecific symptoms and signs of cancer. ○
- 17 The clinical experience of the prognosis in opposite CEA and image change after therapy in stage IV colorectal cancer. **2022**, 12, ○
- 16 DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand?. ○
- 15 A novel prognostic model of gastric cancer patients based on cachexia status by using plasma exosome-derived miRNAs. ○
- 14 Survival nomograms for simultaneous resection of primary and hepatic lesions without neoadjuvant chemotherapy in patients with resectable colorectal liver metastasis. ○
- 13 Diagnostic and economic value of carcinoembryonic antigen, carbohydrate antigen 19-9, and carbohydrate antigen 72-4 in gastrointestinal cancers. 29, 706-730 ○
- 12 Glycoproteins and Cancer Biomarkers. **2023**, 195-227 ○
- 11 The role of oxidative stress, tumor and inflammatory markers in colorectal cancer patients: A one-year follow-up study. **2023**, 62, 102662 ○
- 10 Molecular characteristics, oncogenic roles, and relevant immune and pharmacogenomic features of NEK2 in gastric cancer. **2023**, 116, 109737 ○
- 9 Combined preoperative prognostic nutritional index and D-dimer score predicts outcome in colorectal cancer. **2023**, 23, ○
- 8 Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1. **2023**, 28, 334-348 ○
- 7 Construction and Validation of a Novel Prognosis Model in Colon Cancer Based on Cuproptosis-Related Long Non-Coding RNAs. **2023**, 12, 1528 1
- 6 Pretreatment Carcinoembryonic Antigen Level Serves as a Potential Biomarker to Guide Adjuvant Radiotherapy in pT4N+ Colon Cancer Patients. **2023**, 2023, 1-5 ○
- 5 Non-steroidal anti-inflammatory drugs and biomarkers: A new paradigm in colorectal cancer. 10, ○
- 4 The Potent G-Quadruplex-Binding Compound QN-302 Downregulates S100P Gene Expression in Cells and in an In Vivo Model of Pancreatic Cancer. **2023**, 28, 2452 ○
- 3 A Large-Scale Proteomics Resource of Circulating Extracellular Vesicles for Biomarker Discovery in Pancreatic Cancer. ○
- 2 Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer. **2023**, 24, 6753 ○

- 1 The importance of tumor markers in patients undergoing resection for lung metastasis of colorectal carcinoma.

o